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4 INTRODUCTION 
 
Bile pigments including bilirubin and biliverdin belong to the class of ‘porphyrin’ 
molecules. These coloured compounds are tetrapyrrolic, dicarboxylic acids that 
are produced in the body. An adult human produces approximately 300mg 
bilirubin per day which is the principal mammalian bile pigment and a catabolic 
end product of the degradation of heme [PETRYKA and HOWE, 1979]. 
Urobilinoids including urobilin and stercobilin are degradation products formed by 
bacterial reduction of bilirubin in the gastrointestinal tract. These compounds 
occur primarily in the stools of human beings and provide the colouration of 
faeces [VITEK et al., 2006].  
For a long time, bilirubin has been associated with toxicity or illness. 
Furthermore, bile pigments have been considered as waste products of heme-
catabolism leading to adverse effects if they accumulate in the body [BULMER et 
al., 2008].  
Over the past 20 years, researchers have expressed their interest to the variety 
of endogenous antioxidant compounds that may prevent oxidative damage 
[TEMME, 2001]. A series of studies has been performed to explain the 
physiological relevance of bile pigments. In the mid 1900s, the beneficial effects 
of bilirubin were described for the first time in an in vivo study. It was found that 
bilirubin can provide antioxidant potential by protecting vitamin A from oxidation 
in the lumen [BERNHARD, 1954]. As mentioned in a recent publication, 
unconjugated bilirubin, biliverdin and bilirubin ditaurate possess antimutagenic 
and antioxidant effects. It was shown that these compounds inhibit the 
genotoxicity of different mutagens in Salmonella bacteria [BULMER et al., 2007]. 
Furthermore, numerous studies have demonstrated that the impact of heme 
oxygenase and slightly increased serum bilirubin concentrations may protect 
against oxidative stress induced diseases, such as atherosclerosis and cancer 
[VITEK and OSTROW, 2009].    
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So far, there are only a few published studies dealing with the beneficial effects 
of stercobilin and urobilin. From 1868 to 1871, researchers examined these two 
bile pigments in urine and feces which are formed by bacterial reduction of 
bilirubin [PETRYKA and HOWE, 1979].  
In continuation of formerly published data on a variety of bile pigments it was the 
aim of the present study to investigate the potential antimutagenic and 
antioxidant properties of stercobilin and urobilin in the Ames Salmonella test. To 
my knowledge, these compounds have never been used before in this test 
model. The bile pigments were tested in the presence of two bacterial strains and 
different mutagens (TNFone, Phip, AFB1 and t-BuOOH) were used to provide the 
formation of mutant revertants. Mutagenicity assays were performed to ensure 
the non-mutagenic potential of stercobilin and urobilin.  
The present study was part of the project: ‘The physiological relevance of bile 
pigments - In vitro to in vivo evidence of antioxidant, anti- mutagenic and anti-
carcinogenic potential and their mechanisms of action’. Principal investigator is 
A.o. Univ.-Prof. Dr. Mag. Karl-Heinz Wagner and his experimental working group 
‘Oxidative stress and DNA damage’.  
The entire research included eight bile pigments. My workmate Gesa Ziesel and 
me investigated the modulatory effects of bilirubin dimethyl ester, biliverdin 
dimethyl ester, stercobilin and urobilin and split these up between the two of us. 
Mag. Christine Mölzer and Hedwig Huber studied the antimutagenic and 
antioxidant effects of bilirubin, biliverdin, bilirubin ditaurate and protoporphyrin 
under the same test conditions. The research activities were funded by the 
Austrian Science Fund (FWF, Vienna).   
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5 LITERATURE SURVEY 
5.1 The Ames test 
5.1.1 Main features of the test procedure 
The Ames Salmonella test is defined as a short-term bacterial reverse 
mutation assay. This assay is used all around the world to determine the 
mutagenic potential of new chemicals and drugs that can produce genetic 
damage that leads to gene mutations. Furthermore, the test is an important 
method for registration or acceptance of various chemicals, including drugs 
and biocides. It is very important to comply with formalities and international 
guidelines (e.g., Organisation for Economic Co-operation and Development 
(OECD); International Commission on Harmonization (ICH)) to ensure 
uniformity of the testing procedures [MORTELMANS and ZEIGER, 2000].   
 
5.1.1.1 Historical aspects 
The Ames Salmonella/microsome mutagenicity assay is named after its 
developer, Dr. Bruce Ames.  
In 1966, Ames and Whitfield used a spot test procedure with several histidine 
mutant strains for screening chemically induced mutagenesis. In order to 
perform the spot test it is necessary to apply a small amount of the test 
chemical directly to the center of an agar plate. A concentration gradient is 
formed after diffusion of the chemical into the agar. Mutagenic chemicals can 
be detected by a ring of revertant colonies surrounding the area where the 
chemical was applied. Toxic effects of a chemical are characterized by a zone 
of growth inhibition [MORTELMANS and ZEIGER, 2000].  
In 1973, Ames et al. established the plate incorporation assay. This assay 
procedure was performed in the present study to investigate the potential 
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antimutagenic and antioxidant effects of stercobilin and urobilin. The 
development of the plate incorporation assay was a major contributing factor 
to the success of the Ames test and replaced spot test or liquid suspension 
procedures. The plate incorporation assay is more sensitive and quantitative 
than the spot test. A further advantage is the easier and cheaper test 
performance [MORTELMANS and ZEIGER, 2000].  
 
5.1.2 The Salmonella typhimurium tester strains 
The Ames test uses a number of different Salmonella typhimurium strains 
which are histidine dependent and contain some type of mutation in the 
histidine operon. The bacterial strains are not able to grow on a minimal 
glucose agar plate unless the cultures are supplemented with a trace amount 
of histidine. That implies that only those bacteria that revert to histidine 
independence (his+) are able to form colonies [BARILE, 1994].  
 
5.1.2.1 Genotypes of the bacterial strains 
In the present study bile pigments were tested in the presence of two bacterial 
strains, TA98 and TA102. As mentioned above, all tester strains are histidine 
dependent by virtue of a mutation in the histidine operon.  
The mutations are of several types (e.g., base substitutions, frameshifts) and 
each tester strain carries a known type of mutation.  
TA98 carries the hisD3052 mutation and TA102 contains the hisG428 
mutation. The hisD3052 mutation is defined as a -1 frameshift mutation and 
influences the reading frame of a nearby repetitive –C–G–C–G–C–G –C-G- 
sequence. Frameshift mutagens, for example 2-nitrofluorenone, are necessary 
for the reversion of the hisD3052 allele [ISONO and YOURNO, 1974].  
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Strain TA102 which carries the hisG428 mutation contains A·T base pairs at 
the site of mutation in contrast to the other Salmonella strains that detect 
mutagens damaging G·C base pairs. Furthermore, TA102 detects a number of 
oxidative mutagens, for example hydroperoxides. HisG428 mutation is an 
ochre mutation that can be reverted by all six possible base-pair changes 
[LEVIN et al., 1982]. 
The plasmid pKM101 is present in both bacterial tester strains and carries an 
ampicillin resistance gene. The R factor plasmid improves the error-prone 
DNA repair. Additional introduction of the multi-copy plasmid pAQ1 in strain 
TA102 contains a tetracycline resistance gene, which is useful for detecting 
the presence of the plasmid [MORTELMANS and ZEIGER, 2000].  
Moreover, strain TA98 and TA102 contain the rfa-mutation which affects the 
characteristics of the bacterial cell wall by inducing a partial loss of the 
lipopolysaccharide barrier. The result is an increased permeability of the cells 
[MORTELMANS and ZEIGER, 2000]. 
Strain TA98 includes the uvrB deletion mutation which appears as a repair 
pathway for DNA damage and eliminates the exact excision repair. As a result, 
more DNA lesions can be repaired by the error-prone DNA repair mechanism. 
This type of shift is not performed in TA102 [AMES et al., 1973]. 
Summing up, it can be said that TA98 is a kind of a frameshift sensitive strain 
that supplies information on frameshift mutations. The tester strain TA102 can 
be described as a base-pair substitution-strain which detects DNA cross-
linking damage and is sensitive to mutagens causing oxidative damage 
[MARON and AMES, 1983]. Before starting the test series the strains were 
checked for genetic integrity.  
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5.1.3 Metabolic activation systems 
Some classes of chemicals are not self-acting and therefore require metabolic 
activation to be biologically active. A distinction is made between oxidative- 
and reductive enzyme systems [MORTELMANS and ZEIGER, 2000].  
 
5.1.3.1 Oxidative metabolism 
  Several carcinogenic chemicals, such aromatic amines or polycyclic aromatic 
amines have to be activated by a metabolic activation system; otherwise they 
would be biologically ineffective. Humans and lower animals possess the 
cytochrome-based P450 system which is present primarily in the liver. This 
metabolic oxidation system is able to metabolize various chemicals into DNA-
reactive, electrophilic forms. A relevant disadvantage of the Salmonella 
typhimurium strains and bacterial test systems in general, is their lack of 
metabolic abilities, including the cytochrome-based P450 metabolic oxidation 
system. This fact has led to the use of an exogenous mammalian organ 
activation system which consists of a 9000xg supernatal fraction of a rat liver 
homogenate [MARON and AMES, 1983]. 
 
5.1.3.2 Reductive metabolism 
A reductive enzyme system can be used for the metabolic activation of 
chemicals containing azo and diazo bonds. A reduction of such chemicals can 
be obtained in the anaerobic intestinal microflora, in the intestinal wall and in 
the liver of mammals, including man. Two different types of reductive in vitro 
systems are commonly in use. Type 1 is based on a liver homogenate 
supplemented with FMN [PRIVAL et al., 1984]. Type 2 is based on rat 
intestinal microflora preparations [REID et al., 1984].  
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5.1.4 Positive and negative controls 
Each experiment in the present study included solvent controls and diagnostic 
positive controls specific for each strain and for the metabolic activation 
system [MORTELMANS and ZEIGER, 2000]. 
 
5.1.4.1 Positive control chemicals 
Diagnostic mutagens are used in the Ames test to ensure the efficacy of the 
S9 rat liver homogenate and the reversion properties of the tester strains. The 
concentration of the positive control should be calculated for each new S9-
charge, because each batch of metabolic activation is subject to fluctuations 
[MORTELSMANS and ZEIGER, 2000].  
 
5.1.4.2 Negative control chemicals 
Each tester strain has a relatively constant number of spontaneous revertant 
colonies. Day-to-day and laboratory-to-laboratory variations usually arise. The 
spontaneous mutant frequency can also be influenced by the utilization of S9. 
For instance, the spontaneous revertant values of strain TA102 will increase in 
the presence of metabolic activation because the strain is highly sensitive to 
the S9 addition [MORTELMANS and ZEIGER, 2000]. 
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Strain 
Number of revertants 
without S9 
 
with S9 
TA97 75-200 100-200 
TA98 20-50 20-50 
TA100 75-200 75-200 
TA102 100-300 200-400 
TA104 200-300 300-400 
TA1535 5-20 5-20 
TA1537 5-20 5-20 
TA1538 5-20 5-20 
Table 1: Ranges of spontaneous revertant colonies in the Ames Salmonella test                                                              
     [modified: MORTELMANS and ZEIGER, 2000] 
 
 
5.2  Bile pigments – History, Chemistry, Metabolism 
5.2.1 Historical background 
Over the years the opinion about the physiological importance of bile pigments 
has considerably changed. These coloured compounds were used in the 
traditional Chinese medicine for thousands of years to prevent and heal 
different diseases like epilepsy, convulsions and tetany. The treatment 
particularly involved the oral supplementation of gall stones and the salts of 
bilirubin. Furthermore, a regular administration should imply life prolonging 
properties [READ, 1976]. In the modern medicine the beneficial properties of 
bile pigments were ignored for a long time. Especially bilirubin was described 
as a useless by-product of heme catabolism that can be toxic [BULMER et al., 
2008].   
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The origin of scientific studies dates back to the 19th century. In that time, the 
term ‘bilirubin’ was established [STADELER, 1864]. Fischer et al. classified all 
potential isomers of protoporphyrin and the mesoporphyrins in fifteen groups 
[FISCHER and ORTH, 1934].   
The history of urobilinoids began in 1868. At this time, Jaffe discovered the 
bile pigment urobilin in urine and feces. Urobilin combined with zinc salts 
showed a strong green fluorescence [JAFFE, 1868]. In 1871, stercobilin was 
identified in feces [LAIR and MASIUS, 1871]. At this time, the formation of 
urobilinoids by heme degradation was still unknown.  
More than forty years later, the identity of these two pigments was proven. 
Further research was done in this field resulting in very important discoveries. 
It was established that stercobilin and urobilin were formed by bacterial 
reduction of bilirubin. The formation of both pigments via bacterial reduction 
was introduced by Maly and later confirmed by other researchers [WATSON et 
al., 1969]. 
 
5.2.2 General chemical aspects 
The term ‘bile pigment’ describes all linear open-chain tetrapyrroles [MC 
DONAGH, 1979]. Tetrapyrroles possess many different functions, such as 
light harvesting pigments in higher plants, energy generation in bacterial and 
eukaryotic cells, antioxidant effects, generation of ROS and cell signaling in 
eukaryotic cells [VITEK and OSTROW, 2009].  
The endogenous pigments, unconjugated and conjugated bilirubin, belong to 
this group. Additionally, bile pigments include biliverdin and the urobilinoids, 
stercobilin and urobilin. These pigments are tetrapyrrolic, dicarboxylic acids 
that belong to the porphyrin family of molecules. These coloured compounds 
possess two propionic acid side chains and are formed in the human body 
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[BULMER et al., 2008]. The unique chemical structure of the porphyrins is 
responsible for their biochemical and genetic features.  
Chlorophylls, hemoglobins and heme-containing enzymes are classified as 
porphyrin derivatives that include metalloporphyrins as the active part [ODIN, 
1997]. All bile pigments contain two free or conjugated propionate groups and 
several double bonds which are susceptible to oxidation. Therefore, these 
pigments can serve as antioxidants by transferring their free electrons to other 
unstable chemicals. The solubility of bilirubin in water and in most lipid 
solvents is poor. Bilirubin dissolves best in hydrogen bond-breaking solvents, 
for example DMSO [OSTROW and CELIC, 1984].  
 
 
 
 
 
 
 
F 
 
 
Figure 1: Two dimensional structure of bilirubin and biliverdin                             
      [BULMER et al., 2008] 
 
 
 
 
unconjugated bilirubin biliverdin 
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 Figure 2: Chemical structures of stercobilin and urobilin                                             
  [VITEK et al., 2006] 
 
5.2.3 Formation of bile pigments 
Bile pigments are formed in humans via the degradation of heme which acts 
as prosthetic group for several hemoproteins (e.g. hemoglobin, myoglobin, 
cytochrome P-450 and peroxidase) [STOCKER, 2004].  
All red blood cells have a limited life span of approximately 120 days. After 
that time, they are degraded by the reticuloendothelial system. The 
phagocytosis takes place in spleen, liver and bone marrow and provides 
approximately 80% of heme. The remaining 20% originate from the catabolism 
of other heme proteins. This pathway is the initial step in the formation of the 
pigments [SCHMID and MCDONAGH, 1975]. 
The first step of heme catabolism is initiated by heme oxygenase-1 which 
requires NADPH and molecular oxygen. This enzyme converts heme to 
biliverdin, carbon monoxide and iron by cleaving the heme ring. Heme 
oxygenase-1 also includes biliverdin reductase which reduces the blue-green 
pigment biliverdin to the yellow pigment bilirubin [STOCKER, 2004].       
As mentioned above, bilirubin is insoluble in water at physiological pH. 
Therefore, bilirubin is present as a complex with albumin in the blood 
circulation. In this form bilirubin is called unconjugated or indirect bilirubin 
[STOCKER et al., 1987].  
urobilin stercobilin 
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Bilirubin dissociates from its carrier protein and is taken up from blood into 
hepatocytes. In the liver, unconjugated bilirubin is conjugated with glucuronic 
acid by the enzyme UDP glucuronosyl transferase (UGT1A1). In this form the 
bilirubin is called conjugated or direct bilirubin. Bilirubin diglucuronide is then 
transported into the bile caniculi and thence into the bile. Finally, the 
conjugated bilirubin reaches the duodenum via the bile duct. There it is 
hydrolyzed to hydrogenated derivatives of bilirubin and finally to urobilinoids by 
bacterial enzymes including β-glucuronidase [STOCKER, 2004].  
The major portions of urobilinoids are excreted into the stool and provide the 
colouration of feces [STOCKER, 2004]. It is established that unconjugated 
bilirubin is reduced to colorless urobilinoids in the gastrointestinal tract by 
intestinal microflora. The most important compounds are urobilinogen and 
stercobilinogen as well as their oxidation products, urobilin and stercobilin 
[VITEK et al., 2006].    
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heme oxygenase 
O2 
biliverdin reductase 
CO 
NADPH 
NADP 
Figure 3: Heme degradation from biliverdin to bilirubin         
      [modified: VITEK and OSTROW, 2009] 
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Approximately 10-15% of the urobilinoids reach the enterohepatic circulation 
which is characterized by reabsorption by hepatocytes, transport through the 
portal vein back to the liver and re-excretion via the bile. A minor portion (1.0-
3.5mg urobilinoids per day) is eliminated from the body in the urine as water-
soluble compounds via the kidneys [KUNTZ and KUNTZ, 2008]. The reduction 
of unconjugated bilirubin to urobilinoids is very efficient; therefore only 5-20mg 
bilirubin per day can be found in stools of humans while the excretion of 
urobilinoids range from 50-250mg per day [WITH, 1968, VITEK et al., 2006].  
The involvement of specific bacteria in the reduction of unconjugated bilirubin 
to urobilinoids is poorly described in the literature. Clostridium perfringens, 
Clostridium ramosum, Clostridium difficile and Bacteroides fragilis are a few 
microbial species which are uncontroversially involved in the reduction [VITEK 
et al., 2000, GUSTAFSSON and LANKE, 1960, FAHMY et al., 1972]. 
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Figure 4: Multiple steps in the reduction of unconjugated bilirubin by intestinal 
      microflora showing the chemical structure of the products formed 
      [VITEK et al., 2006] 
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5.2.4 Bile pigments in mammals and other animals 
The physiological plasma bilirubin concentration in the human body ranges 
from 5 to 17µM/l. A concentration over 300µM/l is related to the occurrence of 
neurologic diseases [STOCKER, 2004]. An elevated circulating unconjugated 
bilirubin concentration of more than 17.1µmol/L is defined as Gilbert 
syndrome. The Crigler-Najjar syndrome is characterized by a concentration of 
335µmol/L [IHARA et al., 1999]. 
The organism produces approximately 300mg bilirubin per day [SCHMID and 
MCDONAGH, 1975]. As mentioned above, in mammals, blue-green biliverdin 
is reduced to yellow bilirubin. Thus, biliverdin acts as a transient intermediate 
of heme catabolism. In some vertebrates (e.g. birds, amphibians, reptiles) the 
heme degradation is interrupted after the formation of biliverdin. In that case, 
biliverdin acts as the predominant endproduct [O´CARRA et al., 1975].  
However, the formation of bilirubin appears to occur also in fish. Therefore, the 
sequence of bile pigment formation (heme → biliverdin → bilirubin) is not 
restricted to human beings and mammals [SCHMID and MCDONAGH, 1979].  
 
5.3 Bile pigments – Harmful and protective aspects 
5.3.1 Harmful aspects and bile pigment related diseases 
 
5.3.1.1 Toxicity of bile pigments 
Only a few studies have been carried out in the past exploring the potential 
toxic effects of bile pigments. The main focus was dedicated to the adverse 
properties of unconjugated bilirubin. These studies reported that bilirubin 
possesses prooxidant and toxic properties referring to its incorrect association 
with neonatal jaundice and brain damage [TOMARO et al., 2002]. Bilirubin has 
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cytoprotective properties at normal to slightly increased concentrations, 
whereas high levels of plasma bilirubin are often cytotoxic [VITEK and 
OSTROW, 2009].  
 
5.3.1.2 Neonatal jaundice and bilirubin encephalopathy 
Neonatal jaundice appears in almost all newborn babies. During the first two 
weeks of life, unconjugated bilirubin concentrations are increased because of 
the degradation of fetal red blood cells and the temporary inability of bilirubin 
glucuronide formation. At the age of one month, the enzyme UDP 
glucuronosyl transferase reaches its fully active and reduces the unconjugated 
bilirubin concentration to the adult level [GOURLEY, 1997]. Therefore, the link 
between unconjugated bilirubin and the development of neonatal jaundice or 
brain damage is not exclusionary, but only relevant at high bilirubin 
concentrations.  
Excessively elevated unconjugated bilirubin is not able to bind albumin and 
therefore it is defined as free unconjugated bilirubin which is highly lipophilic. 
This fraction can diffuse into cells by passive diffusion and causes toxic 
effects. Unconjugated bilirubin at high concentration can cause various types 
of neurological dysfunctions (e.g. kernicterus) which are known as bilirubin 
encephalopathy. Newborn infants are particularly at risk of brain damage.  The 
increased susceptibility is caused by the delayed development of the hepatic 
conjugation system (e.g. in premature infants), the reduced binding capacity of 
albumin and possible genetic lesions (e.g. Crigler-Najjar syndrome patients) 
[SHAPIRO, 2003]. 
 
5.3.1.3 Crigler-Najjar-syndrome 
A further example for an unconjugated hyperbilirubinemia is the Crigler-Najjar 
syndrome. This potentially lethal disorder is characterized by an increased 
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unconjugated bilirubin concentration (15-50mg/dl) in the plasma resulting from 
a deficiency of the uridinediphosphoglucuronate glucuronosyl transferase. This 
enzyme is predominately responsible for the detoxification and excretion of 
bilirubin [GANTLA et al., 1998]. In 1952, the rare syndrome was described by 
Crigler and Najjar and was formerly called “a severe congenital familial non-
hemolytic jaundice with kernicterus”. Possible treatments are orthotopic liver 
transplantation and phototherapy [CRIGLER and NAJJAR, 1952]. 
 
5.3.1.4 Gilbert Syndrome 
Gilbert Syndrome is a relatively common disorder (3-17% of the general 
population) which is characterized by a mildly increased serum bilirubin 
concentration of approximately 17µmol/L. Individuals with Gilbert syndrome 
have a reduced activity of the enzyme UDP glucuronosyl transferase. This 
enzyme is needed for the synthesis of hepatic uridine diphosphate 
glucuronosyl transferase (UGT1A1). In healthy people, UGT1A1 conjugates 
bilirubin and eliminates it from the body. The UGT1A1 polymorphism 
(UGT1A1*28) is characterized by decreased bilirubin excretion and increased 
unconjugated bilirubin levels [IHARA et al., 1999, BULMER et al., 2008].   
Numerous studies have been published during the past years demonstrating 
the positive effects of mildly elevated serum bilirubin concentrations in the 
prevention of oxidative stress-mediated disorders, especially atherosclerotic 
diseases [NOVOTNY and VITEK, 2003]. Furthermore, individuals with Gilbert 
syndrome suffer lower rates of cardiovascular diseases contrary to individuals 
with reduced or normal serum bilirubin levels [BULMER et al., 2008]. 
Therefore, investigating bile pigments’ mechanism of action constitutes an 
exciting new field of research.  
In 2008, Bulmer et al. examined the reasons for decreased risk of 
cardiovascular disease in Gilbert syndrome patients compared to healthy 
individuals. The authors investigated several markers (plasma antioxidant 
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status, erythrocytes antioxidant enzyme activities, plasma malondialdehyde, 
blood lipid profile, resistance to serum oxidation) in 21 subjects. Nine 
individuals represented the Gilbert syndrome group, whereas the remaining 
twelve were controls. It was established that the Gilbert syndrome group was 
characterized by a significantly higher trolox equivalent antioxidant capacity 
and significantly increased concentrations of unconjugated bilirubin. The 
antioxidant activity was measured by FRAP-test (ferric reducing ability of 
plasma) which showed significantly better results in the Gilbert syndrome 
individuals. Additionally, the Gilbert syndrome patients were characterized by 
a 13.6% improved resistance to serum oxidation compared to controls.  
This study represented the first attempt to investigate the mechanism how 
bilirubin could protect from cardiovascular disease. In order to realize the 
important beneficial effects of bile pigments, this still unknown mechanism has 
to be explained. After their mechanism of action has been clarified, 
researchers could use the physiological effect of bile pigments to prevent 
cardiovascular diseases and cancer [BULMER et al., 2008]. 
 
5.3.1.5 Cell proliferation 
Only a few studies have been designed in the past to explain the potential cell 
stimulating effects of biliverdin. A significant result in this field was yielded by 
Lafarge-Frayssinet et al. who studied the promoting effects of biliverdin for 
hepatic cells mediated by AFB1. The authors demonstrated that, in the 
presence of AFB1, biliverdin enhanced the impact of neoplastic liver cell 
transformation. In the absence of AFB1, this observation was not confirmed 
[LAFARGE-FRAYSSINET et al., 1983]. Although some studies suggest 
biliverdin can stimulate cell growth, it is important to review the findings 
critically due to the high and hence non physiological biliverdin concentrations 
that have been assayed [BREINHOLT et al., 1995].  
 
  
Literature survey 
 
20 
 
5.3.2 Protective aspects 
In the past 20 years, the physiological relevance of bile pigments has been 
growing. Numerous studies have been carried out during the last years to 
investigate the beneficial effects of bile pigments. As already mentioned, the 
majority of research is dealing with the positive properties of bilirubin and 
biliverdin. These compounds are said to possess antioxidant, antimutagenic, 
anti-complement, anti-viral and anti-apoptotic effects [DUDNIK et al., 2001, 
ROMERT et al., 1994, NAKAGAMI et al., 1993]. Only a few studies have been 
published dealing with the beneficial properties of stercobilin and urobilin. To 
my knowledge, these compounds have never been used before to investigate 
their antimutagenic and antioxidant potency in the Ames Salmonella test.  
Furthermore, numerous papers have been published exploring the positive 
effects of hemin, chlorophyllin and related pyrrole pigments [ARIMOTO et al., 
1995].  
Nowadays, the proof of antimutagenic and anticarcinogenic compounds is of 
great importance due to the negative effects of an increased mutation rate and 
the related cancer risks [ODIN, 1997]. 
 
5.3.2.1 Antioxidant potential of bile pigments 
Antioxidants are a group of compounds that delay or inhibit the oxidation of an 
oxidizable substrate. There are two groups of antioxidants, enzymatic and 
non-enzymatic. The enzymatic antioxidant system includes superoxide 
dismutase (SOD), catalase (CAT) and glutathione-peroxidase (GPx). Non-
enzymatic antioxidants are vitamin A, vitamin C, vitamin E, flavonoids, uric 
acid and bilirubin [HALLIWELL and GUTTERIDGE, 1985]. Non enzymatic 
antioxidants are essential in cellular defense, whereas enzymatic antioxidants 
are more important in the extracellular space [STOCKER, 2004].   
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Many studies have been published in the last years to elucidate the possible 
antioxidant properties of bile pigments, particularly of unconjugated bilirubin 
and biliverdin. To my knowledge, only one study has been carried out to 
investigate the antioxidant activity of urobilinoids. In this section the postulated 
antioxidant effects of bile pigments will be presented and discussed.   
In 1953, Bernhard et al. studied the antioxidant activity of bile pigments for the 
first time. It was shown that unconjugated bilirubin and biliverdin protect 
vitamin A from oxidation [BERNHARD et al., 1954]. More than 60 years later, 
Stocker et al. reawaked the interest in bilirubin and its antioxidant potential. 
The authors showed that bilirubin was a more efficient peroxyl radical 
scavenger than α-tocopherol and vitamin C [STOCKER et al., 1987].  
In a subsequent experiment, Stocker et al. studied the antioxidant potential of 
albumin-bound bilirubin at concentrations found in plasma of healthy men. The 
results indicated that albumin-bound bilirubin inhibited the oxidation of 
albumin-bound fatty acids in vitro, particularly of albumin-bound linoleic acid. 
1mol of albumin-bound bilirubin was able to scavenge 2mol of peroxyl 
radicals. Furthermore, the antioxidant potential of albumin-bound bilirubin was 
compared to ascorbate and urate. It was demonstrated that albumin-bound 
bilirubin was more or less equally effective in scavenging peroxyl radicals like 
uric acid, but less effective than vitamin C. In conclusion, the authors 
established that albumin-bound bilirubin has antioxidant properties and acts as 
an endogenous antioxidant [STOCKER et al., 1987].  
A growing body of evidence supports the view that albumin-bound bilirubin is 
also able to prevent proteins of being oxidatively damaged by different types of 
reactive oxygen and nitrogen species (RONS) [STOCKER, 2004]. 40% of the 
human albumin is located in the blood circulation, whereas the remaining 60% 
is present in the extracellular space. Thus, the antioxidant potential of albumin-
bound bilirubin is not restricted to the plasma [BRODERSEN and STERN, 
1980]. Further research revealed that albumin was present in inflammatory 
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exudates after leaving the blood circulation. This implies a higher possibility for 
antioxidant activity at sites of elevated occurrence of RONS by phagocytic 
cells [STOCKER, 2004]. 
Further research suggests that bile pigments possess antioxidant properties 
towards lipid oxidation. In 1995, Hulea et al. studied the antioxidant effects of 
free and albumin-bound bilirubin at concentrations found in blood plasma. 
These two compounds were tested for their potency to inhibit the metal-
catalyzed oxidation of low density lipoprotein (LDL). Several markers were 
used for determining LDL peroxidation (decreased reactivity of thiobarbituric 
acid, electrophoretic mobility changes, fewer apo B fragmentations, reduced 
quantity of cholesterol oxidation products). It was shown that the albumin-
bilirubin complex suppressed the metal-catalyzed oxidation of LDL in a dose 
depent manner. In conclusion, bilirubin protected against oxidation of lipid 
membranes in vitro. Interestingly, the inhibition in the LDL-iron-BR system 
(54% inhibition) was more effective than in the copper-catalyzed reaction (30% 
inhibition). This could be due to the fact that bilirubin and copper can form an 
unstable complex [HULEA et al., 1995]. 
The antioxidant activity of urobilinoids was first described in 1996 by 
Nakamura et al. who showed that these reductive bilirubin metabolites have 
an antioxidant function. Urobilinoids had not been used previously to 
investigate their antioxidant potential and their specific function.  
Nakamura et al. prepared a synthetic urobilinogen for the experiment which 
was defined as i-urobilinogen. The synthesis of the metabolite was based on 
the reduction of commercial bilirubin. NMR analysis and mass spectroscopy 
were used for structural conformation [NAKAMURA et al., 2006].   
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Figure 5: Metabolism and structures of fecal pigments in mammals                
      [NAKAMURA et al., 2006] 
 
The aim of the previously mentioned study was to explore the radical 
scavenging potential of urobilinogen compared with other antioxidants 
(bilirubin, α-tocopherol and β-carotene). The radical DPPH (1,1-diphenyl-2-
picrylhydradyl) was used to evaluate antioxidant potential. Furthermore a 
“challenge test” was incorporated into the study to investigate the effects of 
urobilinogen on the formation of linolate hydroperoxide by AMVN (2,2-azobis 
(2,4-dimethylvaleronitrile)). Generally speaking, antioxidant potential is 
essential to inhibit the formation of linolate hydroperoxide. In order to explore 
the effects on the formation, HPLC was used. The DPPH radical trapping 
effects of the antioxidants were established by a UV/VIS spectrophotometer at 
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517nm absorption. In order to determine the radical scavenging activity, each 
antioxidant sample was compared to the absorbance of a blank test. It was 
shown that urobilinogen was the most potent among the other antioxidants. 
The bilirubin metabolite decreased the absorption by 79% of the control, 
whereas α-tocopherol and β-carotene showed a 35 and 29.1% reduction in 
absorption, respectively. The DPPH radical scavenging activity of bilirubin 
amounted 72% of the control. A similarly positive effect of urobilinogen was 
obtained in the “challenge test”. In the presence of urobilinogen, the formation 
of linolate hydroperoxide was inhibited by 50%. The authors concluded that 
urobilinogen was able to inhibit lipid oxidation induced by free radicals 
[NAKAMURA, 2006]. 
 
5.3.2.2  Antimutagenic activity of bile pigments 
A number of studies have been published to elucidate the antimutagenic 
potential of bile pigments. Most of the studies have used the Ames Salmonella 
test for their experiments which is a suitable test system for exploring the 
antimutagenic activity of different compounds. This section includes important 
findings for bilirubin, biliverdin and related pyrrole pigments in this field and the 
major differences are summarized in Table 2.   
In 1980, researchers studied the antimutagenic effects of bilirubin, biliverdin, 
hemin and chlorophyllin against benzo[α]pyrene (B[α]P) in the Ames 
Salmonella test. B[α]P is characterized as a polycyclic aromatic hydrocarbon 
which is often used in the Ames test. The assays were performed in the 
presence of metabolic activation with the Salmonella typhimurium strain TA98. 
It was established that all compounds inhibited the B[α]P induced 
mutagenicity. Hemin showed the greatest antimutagenic effect, followed by 
chlorophyllin, bilirubin and biliverdin [ARIMOTO et al., 1980].  
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This fact was confirmed in 1995 by Arimoto et al. who reported the 
antimutagenic properties of hemin, chlorophyllin, bilirubin, biliverdin, 
protoporphyrin, Fe- and Cu-chlorins in the Ames Salmonella test. These 
compounds were investigated for their potential to inhibit the mutagenicity of 
B[α]P and the metabolites benzo[α]pyrene-7,8-diol, benzo[α]pyrene-4,5-
epoxide and benzo[α]pyrene-7,8-diol-9,10-epoxide. The tests were carried out 
with and without metabolic activation in the presence of the Salmonella 
typhimurium strain TA100. All assays were performed with a preincubation 
time of 30min. The authors reported that bilirubin and biliverdin inhibited the 
mutagenicity of B[α]P with and without metabolic activation. In contrast, the 
bile pigments provided only slightly antimutagenic properties against B[α]P4,5-
epoxide and B[α]P-7,8-diol-9,10-epoxide and benzo[α]pyrene-7,8-diol. Hemin 
was most effective against the mutagenicity of all mutagens. It was also shown 
that hemin and Fe-chlorin inhibited the enzymatic formation of 3-OH-B[α]P. A 
similar effect was not observed for the bile pigments. In order to investigate 
the mechanism of the effective inhibition of the 3-OH-B[α]P formation the 
compounds were incubated with benzo[α]pyrene-7,8-diol-9,10-epoxide. The 
different stabilities on the B[α]P metabolites were monitored with a 
spectrophotometer. A degradation of benzo[α]pyrene-7,8-diol-9,10-epoxide 
was observed with hemin and Cu-chlorin, whereas bilirubin and biliverdin 
showed no effects.  
To conclude, these two studies have shown that bile pigments inhibited the 
B[α]P induced mutagenicity in the Ames Salmonella test. Bilirubin and 
biliverdin were not effective in speeding up the degradation of B[α]P 
metabolism [ARIMOTO  et al., 1980, ARIMOTO et al., 1995]. 
Tang and Edenharder investigated whether porphyrins including hemin, 
chlorophyllin, chlorophyll, biliverdin and bilirubin could inhibit the mutagenic 
effects of 2-nitrofluorene (2-NF), 3-nitrofluoranthene (3-NFA) and 1-
nitropyrene (1-NP). These mutagens are tetracyclic (3-NFA, 1-NP) and tricyclic 
(2-NF) nitroarenes. Additionally, vitamins and fruit juices were tested for their 
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antimutagenic potential. The antimutagenic effects of these compounds have 
been tested in the Salmonella typhimurium strain TA98. All Ames assays were 
performed without metabolic activation. It was shown that all tested 
compounds had antimutagenic effects against the three tested mutagens. 
Hemin and bilirubin were the most potent antimutagens, whereas biliverdin 
and chlorophyllin showed less antimutagenic potential [TANG and 
EDENHARDER, 1997].     
In 2007, Bulmer and colleagues studied the antimutagenic and antioxidant 
effects of bile pigments in the Ames Salmonella test. Unconjugated bilirubin, 
biliverdin and bilirubin ditaurate (a synthetic, water soluble conjugate) were 
tested in six different concentrations with three Salmonella typhimurium tester 
strains (TA98, TA100 and TA102). The bile pigments were studied for their 
potential to inhibit the mutagenicity of various mutagens including 
benzo[α]pyrene (B[α]P), trinitrofluorenone (TNFone), 2-aminofluorene (2-AF), 
sodium azide (NaN3) and tertiary-butyl hydroxyperoxide (t-BuOOH). The 
assays were performed with (B[α]P, 2-AF and t-BuOOH) and without 
metabolic activation. The assays with TNFone, NaN3 and t-BuOOH were 
conducted without S9. It was shown that unconjugated bilirubin, biliverdin and 
bilirubin ditaurate were antimutagenic and antioxidative against all mutagens, 
except for NaN3. In this study, the Salmonella tester strain TA102 was used for 
the first time to investigate the antimutagenic and antioxidant effects of bile 
pigments. It was shown that bilirubin, biliverdin and bilirubin ditaurate were 
able to inhibit the genotoxic effects of t-BuOOH induced oxidative stress 
[BULMER et al., 2007].   
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Author                    Salmonella strain    Compounds            Mutagen                       Metabolic activation        Results, Discussion 
 
Arimoto et al.   
 
1980 
 
TA98 
 
hemin, 
chlorophyllin  
BR                      
[0-1,6µmol/plate] 
BV                      
[0-0,75µmol/plate] 
 
 
B[α]P 
       
with metabolic 
activation 
 
 
Effects of compounds against B[α]P: 
hemin>BR>chlorophyllin>BV 
ID50 (BR/BV/hemin): 0.05/0.5/0.01µmol  
 
 
 
 
 
Arimoto et al.   
1995 
 
TA100 
 
hemin, 
chlorophyllin, 
protoporphyrin,             
BR, BV,                     
Cu-chlorin,                   
Fe-chlorin 
 
B[α]P, B[α]P(7,8)D, 
B[α]P(4,5)E, 
B[α]P(7,8)D(9,10)E 
 
 
B[α]P, 2-AF, t-BuOOH 
(with S9) 
TNFone, NaN3, t-
BuOOH (without S9) 
with and without S9 
 
 
Effects of compounds against B[α]P: 
hemin=protoporphyrin>hematoporphyrin=                                  
Cu-chlorin>                                                                              
Fe-chlorin≥chlorophyllin>BR>BV  
 
Effects of compounds against B[α]P(4,5)E: 
hemin>chlorophyllin>protoporphyrin>  
hematoporphyrin>BR=BV                                                                      
BR and BV inhibited the mutagenic effects                                          
of B[α]P with/without S9.                                                                        
They do not speed up the reduction of B[α]P 
metabolites.    
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Tang and 
Edenharder  
1997 
 
TA98 
 
hemin, 
chlorophyllin, 
chlorophyll 
 
BR [7µmol/plate] 
 
BV[1µmol/plate] 
 
2-NF, 3-NFA, 1-NP 
 
without S9 
 
 
Effects of compounds against                                                    
all                                                                               
three mutagens: BR>BV   
 
ID50 for 2-NF (BR/BV/hemin): 0.05/0.39/0.04µmol 
 
ID50 for 1-NP (BR/BV/hemin): 0.04/0.7/0.02µmol 
 
ID50 for 3-NF (BR/BV/hemin): 0.04/0.11/0.05µmol 
Bulmer et al.  
2007 
TA98, TA100, 
TA102 
BR, BV, BRT 
[0-2µmol] 
B[α]P, TNFone,     
2-AF, NaN3,               
t-BuOOH 
B[α]P, 2-AF, t-BuOOH 
(with S9) 
TNFone, NaN3,                      
t-BuOOH (without S9) 
 
 
Antimutagenic effects of bile pigments                               
against all mutagens, except NaN3. 
BR≥BRT>BV (TNFone) 
BV≥BRT≥BR (2-AF) 
BV>BRT>BR (B[α]P) 
BR≥BV>BRT (t-BuOOH) 
ID50 (BR/BV/BRT): 0,557/1/2,756µmol 
Table 2: The antimutagenic potential of bile pigments and related pyrrole pigments in the Ames test [modified: BULMER et al., 2008] 
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5.3.2.3 Other postulated effects of bile pigments 
As previously mentioned, the enzyme heme oxygenase-1 catalyzes the 
degradation of heme to biliverdin, carbon monoxide and iron and subsequently 
to bilirubin by biliverdin reductase. A number of studies have shown that this 
enzyme is able to prevent oxidative stress by decreasing the amount of ROS 
(reactive oxygen species). These studies established, amongst other findings, 
that heme oxygenase-1 is highly overproduced in atherosclerotic lesions in 
humans [WANG et al., 1998]. Further research revealed that heme oxygenase-
1 is an important protective factor which is lowly expressed in vascular diseases 
and cancer [EXNER et al., 2004].  
As mentioned above, bilirubin has strong antioxidant and antimutagenic 
properties in vitro. This fact was confirmed and supported by several clinical 
observations. An increased body of evidence confirms that bilirubin acts as 
protective factor in several diseases including atherosclerosis, cancer, 
inflammatory and autoimmune disorders [VITEK and SCHWERTNER, 2007].  
In 2001, the link between serum bilirubin concentrations and the mortality of 
cardiovascular diseases and cancer was a study background by Temme et al.  
The risk of cancer mortality was divided into three groups, total cancer, lung and 
non-lung cancer. Additionally, total mortality was examined. The 10-year follow-
up mortality data of approximately 10.000 subjects were provided from the 
Belgium Inter-university Research on Nutrition and Health study. The 
representative sample of the Belgian population included 5450 men and 4843 
women. Serum bilirubin concentrations of men and women were classified into 
five groups (≤ 0.2, 0.3, 0.4, 0.5, ≥ 0.6 mg/dl) and four groups (≤ 0.2, 0.3, 0.4, ≥ 
0.5 mg/dl), respectively. In order to reduce the number of confounders, some 
variables were adjusted (age, smoking status, body mass index, total 
cholesterol concentrations). Temme et al. reported that men in the highest 
range (≥ 0.6mg/dl) of serum bilirubin concentrations had a 27% lower total 
mortality risk compared with men in the lowest range (≤ 0.2mg/dl). Furthermore, 
men in the fifth group showed a significantly lower risk (58%) for total cancer 
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compared with men in the first group. Data observed for non-lung cancer were 
significant. The association between serum bilirubin concentration and mortality 
was not shown for cardiovascular diseases. Women in the highest range (≥ 
0.5mg/dl) of serum bilirubin concentrations showed a 24% lower risk for total 
cancer compared with women in the lowest range (≤ 0.2mg/dl). However, this 
observation was not significant. Furthermore, inverse associations for total 
mortality and cardiovascular diseases were not established in women. A p-
value of 0.05 was considered as significant [TIMME et al., 2001].    
 
                                                          Serum bilirubin [mg/dl] 
                                                          ≤ 0.2                   ≥ 0.6 
 
p-value 
No. of men 740 1190  
Total mortality 
Deaths/1000 person-years 19.2 10.6  
No adjustment 1.00 0.55 (0.43-0.70) 0.0001 
adjusted 1.00 0.73 (0.57-0.94) 0.0960 
Cardiovascular diseases 
Deaths/1000 person-years 6.0 4.6  
No adjustment 1.00 0.78 (0.52-1.2) 0.4306 
adjusted 1.00 1.02 (0.68-1.5) 0.3667 
Total cancer 
Deaths/1000 person-years 7.6 2.4  
No adjustment 1.00 0.31 (0.20-0.49) 0.0001 
adjusted 1.00 0.42 (0.26-0.68) 0.0040 
Table 3: Association between mortality risk and highest and lowest serum   
    bilirubin concentration in men (relative risk and confidence interval)          
    [modified: TEMME et al., 2001] 
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This prospective study showed that the determination of serum bilirubin 
concentrations could be a helpful tool to evaluate the relative cancer risk 
[TIMME et al., 2001].  
 
Furthermore, bile pigments may possess cell apoptotic and regulatory effects 
on carcinogenesis. For example, bilirubin and carbon monoxide provide 
endothelial protection by an active PETN metabolite (Pentaerithrityl tetranitrate) 
[OBERLE et al., 2003].  
                                                          Serum bilirubin [mg/dl] 
                                                          ≤ 0.2                 ≥ 0.5 
 
p-value 
No. of women 1343 950  
   Total mortality 
Deaths/1000 person-years 7.0 5.6  
No adjustment 1.00 0.78 (0.55-1.1) 0.8414 
adjusted  1.00 0.87 (0.62-1.2) 0.5771 
   Cardiovascular diseases  
Deaths/1000 person-years 2.7 2.6  
No adjustment 1.00 0.96 (0.57-1.6) 0.9274 
adjusted 1.00 1.04 (0.62-1.8) 0.7392 
  Total cancer 
Deaths/1000 person-years 2.0 1.3  
No adjustment 1.00 0.70 (0.36-1.4) 0.3014 
adjusted 1.00  0.76 (0.39-1.5) 0.1562 
Table 4: Association between mortality risk and highest and lowest serum     
    bilirubin concentration in women (relative risk and confidence interval)   
    [modified: TEMME et al., 2001] 
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Further research has demonstrated that bile pigments might possess antiviral 
properties. 15 different compounds were tested for their potential to inhibit HIV-
1 protease activity. Additionally, their effects in HIV-1 viral maturation were 
examined. Of these 15 compounds, only bilirubin, biliverdin, secalonic acid D 
and alphazurin suppressed human and simian immunodeficiency virus protease 
activity by blocking viral entry into HeLaT4 target cells. Furthermore it was 
shown that stercobilin, urobilin, biliverdin dimethylester and xanthobilirubic acid 
have similar antiviral properties under the same conditions. However, results of 
cell culture experiments provided no inhibition of HIV-1 viral maturation by these 
compounds. The results of this study suggest that increased bile pigment 
concentrations may affect the course of HIV infections [McPHEE et al., 1996].  
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6 MATERIALS AND METHODS 
6.1 General principles of the Ames test 
The Ames Salmonella test is defined as a short-term bacterial reverse mutation 
assay which is a popular and frequently used test system for the detection of 
chemicals and drugs that can induce mutations [MORTELMANS and ZEIGER, 
2000]. This assay was used to investigate the possible antimutagenic and 
antioxidant effects of stercobilin and urobilin. Furthermore, mutagenicity assays 
were performed with both bile pigments. In principle the test procedure followed 
the standard plate incorporation assay which had been established by Bruce 
Ames in 1973 [MARON and AMES, 1973]. 
6.2 Solutions used for the assay procedure 
6.2.1 Ampicillin solution 
0.2mg Ampicillin was solubilised in 25ml of 0.2N sodiumhydroxide. After mixing 
the solution was strained through an aseptic filter. This antibiotic solution could 
be stored at 4°C for four weeks.  
 
6.2.2 Tetracycline solution 
80mg of tetracycline was solubilised in 10ml of 0.2N hydrochloric acid. After 
mixing the solution was aseptically filtered. This antibiotic solution could be 
stored at 4°C for two weeks.  
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6.2.3 Glucose solution (40%) 
For a 40% solution 400g of glucose was dissolved in 1000ml of boiling 
deionised water. The prepared solution was autoclaved each time before use.  
 
6.2.4 Glucose-6-phosphate solution (304mg/ml) 
1g of glucose-6-phosphate was dissolved in 3.289ml of deionised water. Finally 
the solution was sterilised through an aseptic filter. Portions of 1ml each were 
stored at -20°C.  
 
6.2.5 Histidine-biotin solution 
30.9mg D-biotin and 24mg L-histidine were weighed into two separate weighing 
boats. After transferring the amino acids into a 250ml Pyrex flask, 250ml of 
deionised water were added. The solution was sterilised each time before use 
and was stored at 4°C.  
 
6.2.6 Histidine solution 
0.25g of histidine was dissolved in 50ml of deionised water. Finally the solution 
was aseptically filtered and stored at 4°C.  
 
6.2.7 Biotin solution 
6.1mg of D-biotin was mixed with 50ml of deionised water. The prepared 
solution was strained through an aseptic filter and stored at 4°C.  
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6.2.8 Overnight culture 
5g of Nutrient Broth No.2 are weighed into a Pyrex flask and filled up to 200ml 
with deionised water. After shaking the solution was autoclaved and as soon as 
the nutrient broth was cooled down strain specific antibiotics were added. For 
strain TA98 625µl ampicillin solution are used, whereas TA102 additionally 
needed 156µl tetracycline solution. Thereof, 
12ml each were transferred into two sterile 
250ml Erlenmeyer flasks. One bacterial colony 
(either TA98 or TA102) was taken with an 
inoculation loop from a master plate and was 
added to the flask. After whirling the flasks were 
recapped with a dabber and aluminium film and 
were shaken in a 37°C incubator for 12 hours at 
55rpm.  
 
6.2.9 Master plates 
For the preparation of two master plates, 3.2g of Oxoid agar were made up with 
200ml of deionised water in Pyrex flasks. Afterwards the prepared solution was 
autoclaved. Next 4.3ml of vogel-bonner- and 10.8ml of glucose solution were 
added. After shaking the flasks 2.17ml of histidine- and 1.3ml of biotin solution 
were added. After the agar was cooled down strain specific antibiotics were 
added:  
Salmonella strain                                      Antibiotics 
TA98                                                           625µl of ampicillin 
TA102                                                         625µl of ampicillin 
                                                                   156µl of tetracycline 
Table 5: Strain specific antibiotics for preparation of the master plates 
Figure 6: OVNC incubated for      
            12 hours at 37°C 
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After the antibiotics were added the agar was poured into sterile Petri dishes, 
the thickness of the agar amounted to approximately 1cm. The prepared master 
plates were left under sterile conditions to dehumidify for 24 hours. After drying 
the requested bacteria strain was taken with an inoculation loop from the 
overnight culture and was applied on the plates lattice-like. The master plates 
were incubated for 48 hours at 37°C and sealed with  a tape after that. Once the 
master plates had been inoculated they could be kept for 2 weeks (TA102) or 
for two months (TA98), respectively at 4°C.  
 
6.2.10    MgCl2/KCl solution 
61.5g of KCl and 40.7g of MgCl2 were dissolved in 500ml of deionised water. 
The solution was sterilised trough an aseptic filter and stored at 4°C. 
 
6.2.11 Minimal glucose agar plates 
For preparation of approximately 320 minimal glucose agar plates eight 1000ml 
Erlenmeyer flasks were needed. Into each flask 11.25g of Oxoid agar are 
weighed and filled up to 700ml with deionised water. The flasks were recapped 
with a dabber and aluminium film, and sterilised in the autoclave together with 
glucose- and vogel-bonner solutions. After about 2 hours the flasks were ready 
to be transferred under the laminar flow. To each of the flasks 15ml of vogel-
bonner solution and 37.5ml of glucose-solution were added under sterile 
conditions. After shaking the warm agar was poured into Petri dishes. The 
poured plates were dried for about 24 hours. The next day they were packed in 
plastic bags and stored at 4°C. The storage time wa s 14 days.  
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6.2.12 NADP solution 
A 0.135g/2ml solution was produced. 1g of NADP was dissolved in 14.814ml of 
deionised water. The solution was sterilised through an aseptic filter and frozen 
in portions of 1ml at -20°C.   
 
6.2.13 S9-Mix 
The use of a rat-liver S9 metabolic activation system was necessary because 
bacteria do not have a cytochrome-based P450 metabolic oxidation system.  
The solution was always prepared fresh and kept on ice throughout the test. For 
a maximum of 100 plates 19.75ml of deionised water, 25ml of PBS buffer 
(without Ca and Mg), 1ml of MgCl2, 2ml of NADP solution and 250µl of glucose-
6-phosphate-solution were pipetted into a sterile 50ml centrifuge tube. At last, 2 
ml of the rat liver homogenate were added. The S9-Mix had to be cooled on ice 
constantly during the test, because the solution contains highly susceptible 
enzymes which are highly susceptible to oxidation. The cooled solution had to 
be used within one hour.  
 
6.2.14 Top agar 
1.2g of Oxoid agar and 1g of sodium chloride were dissolved in 200ml of 
deionised water and autoclaved just before each test. Before use, 20ml of the 
histidine-biotin solution are added. The top agar had to be kept in a water bath 
at 55°C throughout the test.  
 
6.2.15 Vogel-Bonner solution 
10g of magnesium sulphate heptahydrate, 100g of citric acid monohydrate, 
500g of dibasic potassium phosphate and 175g of sodium ammonium 
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phosphate tetrahydrate were dissolved in 670ml of deionised water (45°C). The 
solution was autoclaved each time before use.  
 
      Substance               Abbreviation/        Source         Order No.        Utilisation 
                                   empirical formula  
 
2-Amino-1-methyl-6-          PhiP          Toronto Research   A617000      Positive control                                                        
phenylimidazo[4,5,-b]                           Chemicals 
pyridine 
Aflatoxin B1                        AFB1                   Sigma           A6636         Positive control 
Agar No I                                                         Oxoid/           LP011P      Plates, Top agar 
Ampicillin Trihydrate                                        Sigma           A6140         MP, OVNC 
D-Biotin                              C10H16N2O3S         Sigma           B4639         MP 
Dimethylsulfoxide               DMSO                  Sigma           D5879         solvent,  
                                                                                                                 negative control 
D-Glucose                          C6H12O6                    Sigma          G8270          GM agar plates, 
Glucose-6-Phosphat Glu-6-P Sigma G7250  S9-Mix 
Potassium chloride      KCl Sigma P5405  S9-Mix 
Potassium 
phosphate dibasic K2HPO4 Sigma P3786 
Vogel-Bonner-     
solution 
L-Histidine C6H9N3O2 Sigma H8125 Top Agar, MP 
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Magnesium chloride MgCl2 · 6H2O Sigma M9272 S9-Mix 
Magnesium sulfate MgSO4 · H2O Sigma M9397 Vogel-Bonner-solution 
Nutrient Broth  Oxoid/Bertoni CM067B OVNC 
Sodium ammonium 
phosphate 
Na2NH2PO4 · 
4H2O Sigma S9638 
Vogel-Bonner-
solution 
Sodium chloride NaCl Sigma S5886 Top Agar 
Sodium hydroxide NaOH Sigma O6203 Ampicillin-
solution 
Nicotinamide 
adenine dinucleotide NADP Sigma N0505 S9-Mix 
Dulbecco´s 
phosphate buffered 
saline 
PBS PAA Laboratories H15002 
Preincubation, 
S9-Mix 
Rat liver homogenate S9 Biomedica/ICN 50412 
Plate 
incorporation 
test with S9-Mix 
Tertiary-Butyl-
hydroxyperoxide t-BuOOH Sigma B2633 
Oxidative 
mutagen 
Tetracycline 
hydrochloride  Sigma T3383 MP, OVNC 
2,4,7-Trinitro-9-
fluorenone TNFone   Positive control 
Citric acid 
monohydrate C6H8O7 · H2O Sigma C1909 
Vogel-Bonner-
solution 
Table 6: Chemicals and reagents used within the test procedure 
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6.3 Experimental design 
Experiments in the bacterial system were designed to explore the potential 
antimutagenic and antioxidant effects of stercobilin (0.01-2µmol/plate) and 
urobilin (0.01-2µmol/plate and 0.0001-2µmol/plate) in the Ames Salmonella test. 
 
6.3.1 Chemicals and reagents 
The bile pigments, stercobilin hydrochloride (S) [34217-90-8] and urobilin 
hydrochloride (U) [28925-89-5], were purchased from Frontier Scientific. In 
order to protect bile pigments from light and avoid possible oxidative events, the 
highly sensitive compounds were sealed with some adhesive tape                
(see Figure 7). The S9 liver homogenate was obtained 
from MP Biomedicals (Illkirch, France).                  
All chemicals and reagents were stored at -80°C if 
necessary. All solutions, glass ware, tubes, pipettes, etc. 
had to be sterile to ensure a contamination free test 
system. The whole equipment was sterilised in an 
autoclave.  
 
6.3.2 Bacterial strains 
The antimutagenic and antioxidant effects of stercobilin and urobilin were tested 
in the presence of two bacterial strains, TA98 and TA102. It is very important to 
use different Salmonella typhimurium tester strains. Since specific mutations 
within the strains make them more sensitive to respond on different mutagens. 
Mutations of the TA102 can be reverted by mutagens that cause oxidative 
damage. The TA102 strain detects cross-linking agents and the TA98 strain 
gives information on frame-shift mutations. Because of that various tester 
strains are essential for the experimental procedure [MARON and AMES 1983].  
             Figure 7: Urobilin hydrochloride 
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6.3.3 Positive control chemicals 
In order to ensure the reversion properties, the specificity of each tester and the 
activity of the S9-mix, diagnostic mutagens (positive control chemicals) were 
used in each Ames assay [MORTELMANS and ZEIGER, 2000]. 
All tests included three positive control tubes (mutagen only). Therefore a 
variety of mutagens including 2, 4, 7-trinitrofluorenone (TNFone), 2-amino-1-
methyl-6-phenylimidazo [4, 5,-b] pyridine (PhiP) and aflatoxin B1 (AFB1) were 
used to confirm the formation of mutant revertants. Furthermore the prooxidans 
tertiary-butyl hydroxyperoxide (t-BuOOH) was used.  
Tests were conducted with and without metabolic activation incorporating the 
addition of the microsomal liver homogenate. The solutions of TNFone, PhiP 
and AFB1 were dissolved in DMSO. The t-BuOOH solution was dissolved in 
deionised water.  
TNFone is a non-planar polycyclic nitro-amine and was previously found in 
certain photocopy processes. In the Ames Salmonella test TNFone turned out 
to be mutagenic with and without metabolic activation. A number of oral feeding 
studies in animals have been carried out in the past showing that TNFone 
caused different lesions including black discoloration of the skin and hair, dark 
brain and gallbladder, lymphoid depletion and seminal vesicle atrophy in rats 
and mice [KARI, 1992].   
 
 
 
 
 
 Figure 8: Three-dimensional structure of TNFone [BULMER et al., 2007] 
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t-BuOOH is an organic hydroperoxide and oxidant which is known as an initiator 
of the lipid peroxidation. Furthermore, t-BuOOH has the potential to increase 
oxidative stress in vivo and therefore this organic peroxide is used as a marker 
for oxidative stress in various cell culture experiments [HWANG et al., 2005].   
 
 
 
 
 
PhiP is a hazardous heterocyclic aromatic amine which may increase the risk of 
cancer in human, in particular colon, prostate and mammary cancer. 
Heterocyclic aromatic amines are generally formed in cooked meats, fish and 
poultry at high temperatures. Furthermore different types of heterocyclic 
aromatic amines are present in tobacco smoke condensate and diesel exhaust 
[TURESKY, 2007].  
Generally speaking, PhiP is a food related mutagen arising when meat and fish 
is grilled or fried and therefore it should be explained whether stercobilin and 
urobilin are able to inhibit the genotoxic effects of this mutagen [TURESKY, 
2007].  
      
 
 
  
 
 
Figure 10: Chemical structure of PhiP [TURESKY, 2007] 
Figure 9: Chemical structure of t-BuOOH [INAMI et al., 2009] 
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Aflatoxins belong to the substance class of mycotoxins which are mainly 
produced as secondary metabolites by Aspergillus flavus and Aspergillus 
parasiticus. These compounds are toxic, mutagenic and carcinogenic. Different 
types of aflatoxins with various potency and carcinogenicity are known, 
important members are aflatoxin B1, B2, G1 and G2. Of these, AFB1 turned out 
to be the most common and toxic aflatoxin in animals and humans. The major 
metabolite of AFB1 is M1 which is primarily present in milk [DIEKMAN and 
GREEN, 1992]. Aflatoxins are food-related mutagens which occur 
predominantly in peanuts, maize and corns [STROKA, 2000].  
 
 
 
 
 
TNFone, PhiP and AFB1 induced genotoxicity was used to test the possible 
antimutagenic effects of stercobilin and urobilin. t-BuOOH induced pro-oxidative 
effects were used to investigate the possible antioxidant potential of these two 
bile pigments. 
                                 without metabolic activation    with metabolic activation 
TA98                        TNFone [0,0001mg/ml]                 Phip [0,1µmol/ml] 
                                                                                      AFB1 [5µg/ml] 
TA102                      TNFone [0,07mg/ml]                     AFB1 [120µg/ml] 
                                  t-BuOOH [0,75*10-6mol/plate]      t-BuOOH [0,75*10-6mol/plate] 
Table 7: General overview of mutagens used in the Ames test 
Figure 11: Chemical structure of AFB1 [HAN et al., 2010] 
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6.3.4 Negative control chemicals 
All tests included six negative control plates which contained DMSO. These 
plates were necessary to determine the spontaneous mutant frequency of the 
Salmonella typhimurium strains TA98 and TA102.  
 
6.4 Assay procedure 
Antimutagenic testing was performed to explain the possible antimutagenic 
effects of stercobilin and urobilin against TNFone, PhiP and AFB1.      
Antioxidant testing was carried out to investigate the possible antioxidant effects 
of the two bile pigments against t-BuOOH. In order to assess the mutagenic 
potential of stercobilin and urobilin, mutagenicity assays were performed for 
each mutagen and each tester strain.  
 
6.4.1 Preparation of the bile pigment samples 
For each test a fresh bile pigment stock solution was prepared. Therefore 9mg 
aliquots of the bile pigments were weighed out into eppendorf cups and 
dissolved in 618µl of DMSO. After mixing, the cups were placed in an ultrasonic 
bath for 3min to dispense the bile pigments homogenously. To elucidate the 
efficacy of the inhibitory action of 
stercobilin and urobilin against the 
mutagenicity of various mutagens, the 
Salmonella assays were performed in 
the presence of varying doses of the 
pigments.                                         
Six different concentrations (2, 1, 0.5, 
0.1, 0.05 and 0.01µmol/plate) of 
stercobilin and eight different  Figure 12: Preparation of urobilin in eight
                   different concentrations 
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concentrations (2, 1, 0.5, 0.1, 0.05, 0.01, 0.005 and 0.001µmol/plate) of urobilin 
were investigated. Only one test for urobilin was conducted with six 
concentrations as it applied for stercobilin (TNFone, TA102).  
 
The following dilution series was established:  
                                         stock solution [µl]                                 DMSO [µl] 
2µmol/plate 320 480 
1µmol/plate 160 640 
0,5µmol/plate 80 720 
0,1µmol/plate 100 [1µM] 900 
0,05µmol/plate 100 [0,5µM] 900 
0,01µmol/plate 100 [0,1µM] 900 
0,005µmol/plate 100 [0,05µM] 900 
0,001µmol/plate 100 [0,01µM] 900 
   Table 8: Preparation of the bile pigment samples 
 
6.4.2 Antimutagenic/Antioxidant assays 
Antimutagenic and antioxidant activities of stercobilin and urobilin were tested in 
a broad ranging spectrum (0.001 to 2µmol/ plate) in TA98 and TA102 whereas 
bile pigments were dissolved in DMSO. Three plates were counted for every 
concentration of each condition. Every assay included three positive control 
tubes (mutagen only) and six negative control (no mutagen, no bile pigment) 
tubes.  
The test procedure consisted of adding 500µl PBS buffer or S9-mix, 100µl of 
histidine dependent overnight culture bacteria, 100µl mutagen solution and 
  
Materials and Methods 
 
46 
 
200µl PBS buffer in positive and negative control. Finally, 200µl bile pigment 
solution were added to the test tubes.  
All assays were performed with a preincubation time of 25 min at 37°C. After 
that time, 2 ml of top agar containing biotin and histidin were added. Finally, the 
contents of the tubes were vortexed and poured onto the surface of minimal 
glucose agar plates.  
As soon as the top agar had hardened 
(after 20-25 min) the plates were placed 
in a 37°C incubator for 48hours.  
After expiration of this time the histidine 
revertant colonies were counted.  
 
 
The white spots were placed onto a flat lamp and counted manually. The 
background lawns of the plates were examined by eye for thinning and for the 
presence of precipitate [MORTELMANS and ZEIGER, 2000].  
 
 
 
 
 
 
 
Figure 13:  Poured plates drying             
         in the incubator for 48h        
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 Figure 14: Diagram depicting the steps involved in the plates incorporation 
        assay [MORTELMANS and ZEIGER, 2000] 
 
 
6.4.3 Mutagenicity assays 
Mutagenicity assays were performed to demonstrate that stercobilin and urobilin 
are not mutagenic. Therefore, the highest and the lowest concentration of the 
bile pigments were screened (0.01 and 2µmol/plate). Every assay included 
three positive control plates and six negative control plates. These tests were 
conducted with and without metabolic activation.  
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In a typical mutagenicity assay the following substances were mixed in the 
positive control tubes: 
• 500µl of PBS buffer or S9-mix 
• 100µl of histidine dependent overnight culture bacteria 
• 100µl of the respective mutagenic substance 
• 200µl of PBS buffer 
 
In a typical mutagenicity assay the following substances were mixed in the 
negative control tubes:  
• 500µl of PBS buffer or S9-mix 
• 100µl of histidine dependent overnight culture bacteria 
• 100µl of DMSO  
• 200µl of PBS buffer 
 
In a typical mutagenicity assay the following substances were mixed in the 
sample tubes:  
• 500µl of PBS buffer or S9-mix 
• 200µl of bile pigment solution  
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6.5 Statistical analysis 
 
6.5.1 Non statistical evaluation  
According to Mortelmans and Zeiger [MORTELMANS and ZEIGER, 2000] a 
non-statistical procedure was used to evaluate the results of Salmonella 
experiments: 
 
• Positive:  
A mutagenic compound forms a reproducible, dose dependent elevation 
in the number of revertant colonies in one or more strains. 
A weak mutagen compound forms a reproducible, dose dependent 
elevation in the number of revertant colonies in one or more strains. 
However, the revertant number is not double the background colonies 
number.  
• Negative:  
A non-mutagenic compound forms no dose dependent elevation in the 
number of revertant colonies in two independent assays.  
• Inconclusive: 
An inconclusive compound cannot be considered as a mutagen or a 
nonmutagen (e.g., if there is a spread of slightly revertant counts or one 
increased count).   
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In order to classify compounds as antimutagenic or promutagenic the following 
equation was used: 
  No. of revertants (test compound) – No. of revertants (negative control) x 100 
      No. of revertants (positive control) – No. of revertants (negative control) 
 
According to this equation, a compound was defined as ‘antimutagenic’ if the 
relative mutagenic response fell below 50%. A compound was assessed to be 
‘promutagenic’ if the relative mutagenic response elevated beyond 200% 
[BULMER et al., 2007]. 
 
6.5.2 Statistical evaluation 
In order to illustrate the collected test data graphically Microsoft Excel 2007 and 
SPSS 17.0 were used. First of all, a Microsoft Excel spreadsheet was created 
including all the counted revertant data to illustrate the modulatory effects of 
stercobilin and urobilin in diagrams and curves (see Figures in chapter 7).  In 
order to determine antimutagenic/antioxidant effects of bile pigments, the 
percent inhibition of revertant colonies compared to the positive control values 
was evaluated. In mutagenicity assays, results were put in relation to negative 
control values. 
Appropriate statistical algorithms were used to illustrate each bile pigment in 
each condition optimally. Therefore the R2 co-efficient was used to quantify the 
strength of the correlation. This coefficient of determination as well as the linear 
equation was superimposed onto the results figures.  
The software SPSS 17.0 was used to analyse statistical significance of the test 
data. First of all, the data were tested for normal distribution using the K-S test 
of goodness of fit (Kolmogorov-Smirnov). This test showed that all data were 
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normally distributed. In order to investigate the revertant growth inhibition 
differences between the bile pigment concentrations related to positive and 
negative control values, the data were analysed with the one-way analysis of 
variance (ANOVA) and the post hoc tests Bonferroni and Scheffe.                     
A p-value < 0.05 was considered significant.   
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7 RESULTS AND DISCUSSION 
The statistical analysis revealed that stercobilin and urobilin show modulatory 
effects towards genotoxicity of different mutagens. As mentioned before, 
stercobilin and urobilin have not previously been investigated in the Ames 
Salmonella test. Therefore, findings might be of high interest and importance. 
The following section gives an overview on all the achieved results. Table 9 
summarizes the collected data for both bile pigments.  
Strain 
Mutagen 
[mol/plate] S9 Compound 
ID50 
[µmol/plate] 
ID75 
[µmol/plate] 
I0.5 
[%] 
Imax 
[%] His
+ 
TA98 
TNFone 
[0.3*10-6] 
- 
 S   
 U           
 2.98* 
4.02* 
5.77* 
17.8* 
15.8 
19.3 
32.3 
50.6 
453 
362 
 
PhiP 
[0.1*10-8] 
+ 
 S 
 U 
 0.29* 
0.35 
3.14 
2.75 
56.8 
48.3 
68.9 
71.9 
442 
488 
 
AFB1 
[1.2*10-8] 
+ 
 S 
 U 
1.73* 
- 
- 
0.18 
43.9 
76.9 
13.1 
78 
274.5 
316 
TA102 
TNFone 
[0.2*10-7] 
- 
 S 
 U 
3.35* 
1.4 
13.4* 
6.08* 
45.8 
54.1 
43.6 
48 
1218 
1218 
 
AFB1 
[2.9*10-7] 
+ 
S 
U 
0.46 
1.35 
- 
7.18* 
40.8 
45 
- 
55.7 
1008 
 764 
 
t-BuOOH 
[0.75*10-6] - 
 S 
 U 
- 
7.15 
- 
- 
2.1 
25.9 
- 
22.8 
1168 
1482 
 
t-BuOOH 
[0.75*10-6] + 
 S 
 U 
4.68 
1.97 
- 
- 
34.4 
50.5 
48.8 
42.9 
2312 
824 
Table 9: The modulatory effects of stercobilin and urobilin on genotoxicity in the   
     TA98 and TA102 Salmonella typhimurium strains                             
      [according to BULMER et al., 2007] 
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• ID50:  bile pigment dose [µmol/plate] required for 50% inhibition of the                                             
 genotoxicity (positive control) 
• ID75:  bile pigment dose [µmol/plate] required for 75% inhibition of the 
 genotoxicity (positive control) 
• I0.5:  inhibition of genotoxic effects [%] at 0.5µmol bile pigment per plate  
• Imax:  inhibition of genotoxic effects [%] at 2µmol bile pigment per plate   
• His+:  mean number in the positive control plates of one and two   
 experiments, respectively 
• *  Result was extrapolated beyond the concentration range tested   
 [BULMER et al., 2007] 
 
7.1 Antimutagenic testing with TA98 
In the presence of Salmonella typhimurium tester strain TA98 stercobilin and 
urobilin were tested for their potency to inhibit the mutagenicity of TNFone, PhiP 
and AFB1. Assays with TNFone were conducted without metabolic activation 
whereas tests with PhiP and AFB1 were performed with S9. Almost all data 
were significantly different from positive control values (p<0.05) and most of the 
assays were repeated under the same conditions.  
 
7.1.1 Mutagenicity induced by TNFone 
Under this condition the tests on antimutagenic effects of stercobilin and urobilin 
were performed without metabolic activation. Figure 15 illustrates that both bile 
pigments inhibited the TNFone (0.0001 mg/ml) induced mutagenic response in 
the strain TA98 in a dose dependent manner. Table 12-16 in the appendix 
provide the single revertant numbers for positive/negative control and different 
bile pigment concentrations. According to the extrapolated ID50 values, 
stercobilin (2.98µmol) was more effective than urobilin (4.02µmol). The latter 
compound showed a significant effect at all tested concentrations (with an 
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exception of 0.1µmol/plate), whereas stercobilin was at or above 1 µmol/ plate 
significantly different from positive control values (p<0.05). In general, the two 
bile pigments showed a common trend at the concentrations 2, 1, 0.5 and 
0.1µmol/plate. Interestingly, lower concentrations of urobilin (0.05, 0.01, 0.005 
and 0.001µmol/plate) increased the number of revertants above the positive 
control level (about 150%). Lower concentrations of stercobilin have leveled off 
at 100%. That implies that high concentrations of these two bile pigments 
effectively inhibited the TNFone induced genotoxic effects, whereas low 
concentrations did not. The coefficient of determination R2 for stercobilin and 
urobilin was 0.86 and 0.94, respectively which expressed a strong correlation 
between single values.      
    
 
Figure 15: The modulatory effects of bile pigments, stercobilin ▲- - - ▲ (S) and 
        urobilin ♦         ♦ (U) towards TNFone induced genotoxicity in TA98   
        Salmonella typhimurium (S≥1µmol/plate, U≥0.5 and U≤0.05, p<0.05) 
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7.1.2 Mutagenicity induced by PhiP 
PhiP (0.1µmol/ml) induced mutagenicity was used to investigate the possible 
antimutagenic effects of stercobilin and urobilin in the presence of metabolic 
activation. Single revertant numbers, mean values and standard deviations can 
be found in chapter 12, table 12-16. Figure 16 shows that the two bile pigments 
suppressed the PhiP induced genotoxic effects in a dose dependent manner. 
The remarkable significant antimutagenic properties of stercobilin and urobilin 
against PhiP followed the same trend. Both compounds were significantly 
effective at any tested concentration (p<0.05). The low ID50 of stercobilin 
(0.29µmol) was similar to that of urobilin (0.35µmol). Interestingly, even low 
concentrations of both bile pigments crossed the 50% line of inhibition. To sum 
up, stercobilin and urobilin showed strong antimutagenic effects towards PhiP 
induced genotoxicity in TA98 at any tested concentration. As mentioned above, 
high R2 values (0.83 and 0.95) confirmed a strong dose dependent correlation.  
 
Figure 16: The modulatory effects of bile pigments, stercobilin ▲- - - ▲ (S) and       
        urobilin ♦       ♦ (U) towards PhiP induced genotoxicity in TA98           
        Salmonella typhimurium (p<0.05 at all concentrations tested) 
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7.1.3 Mutagenicity induced by AFB1 
In this condition, stercobilin and urobilin were tested for their antimutagenic 
effects in the presence of metabolic activation. Figure 17 clearly shows that 
urobilin was more effective than stercobilin. More specifically, urobilin showed 
strong significantly antimutagenic effects against AFB1 (5µg/ml), even at lower 
concentrations (p<0.05). A decrease in revertants was observed at higher 
concentrations and vice versa. Furthermore, R2 of 0.864 pointed out a strong 
correlation which ensured the results concerning antimutagenicity.   
Generally speaking, stercobilin showed weak antimutagenic effects against 
AFB1 characterized by an extrapolated ID50 value of 1.73µmol. Interestingly, 
stercobilin showed neither a dose-relation nor a twofold reduction of revertants. 
However, significant effects at any tested concentration (p<0.05), except for 2 
µmol/plate (p=0.852), could be observed.    
 
Figure 17: The modulatory effects of bile pigments, stercobilin ▲- - - ▲ (S) and       
        urobilin ♦       ♦ (U) towards AFB1 induced genotoxicity in TA98   
        Salmonella typhimurium (S≤1µmol/plate, U at all concentrations tested, 
        p<0.05) 
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7.2 Antimutagenic and antioxidant testing with TA102   
Salmonella typhimurium indicator strain TA102 was used to study the 
antimutagenic and antioxidant properties of stercobilin and urobilin against the 
mutagenicity of TNFone, AFB1 and t-BuOOH.  
TNFone as well as t-BuOOH were tested without a metabolic activation system. 
Furthermore, t-BuOOH and AFB1 were tested in the presence of S9.  
Almost all data were significantly different from positive control values (p<0.05) 
and most of the assays were repeated under the same test conditions.  
In 2007, Bulmer et al. used the tester strain TA102 for the first time to 
investigate the antimutagenic and antioxidant effects of bile pigments (bilirubin, 
biliverdin, bilirubin ditaurate) in the Ames Salmonella test [BULMER et al., 
2007].         
 
7.2.1 Mutagenicity induced by TNFone  
To elucidate the efficacy of inhibitory action of stercobilin and urobilin against 
the mutagenicity of TNFone (0.07mg/ml), the Salmonella assays were 
performed without metabolic activation.  
Both bile pigments showed a significant and dose-dependent inhibition of 
TNFone induced genotoxic effects (p<0.05). The ID50 for stercobilin and urobilin 
was approximately 3.35 and 1.4µmol, respectively. According to this value 
urobilin was more effective than stercobilin.  
In general, both compounds shared a common trend in suppressing the number 
of His+ revertants compared to the positive control values (see Figure 18). 
Furthermore, high concentrations of stercobilin and urobilin reduced the number 
of revertants approximately by 50%.       
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7.2.2 Mutagenicity induced by AFB1 
In this condition the antimutagenic effects of stercobilin and urobilin were tested 
in the presence of metabolic activation. 120mg/ml AFB1 was used as mutagen.  
Urobilin inhibited the AFB1 induced mutagenic response in a dose dependent 
manner. All used concentrations provided strong significant antimutagenic 
effects (p<0.05). In order to inhibit 50% of positive control, 1.35µmol urobilin per 
plate were needed. Furthermore, a twofold reduction was achieved at the 
highest concentration tested (see Figure 19).     
Under these conditions, only an antimutagenic tendency could be observed for 
stercobilin. More precisely, no dose-related inhibitory response could be 
Figure 18: The modulatory effects of bile pigments, stercobilin ▲- - - ▲ (S) and       
        urobilin ♦        ♦ (U) towards TNFone induced genotoxicity in TA102         
        Salmonella typhimurium (p<0.05 at all concentrations tested) 
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observed. However, 0.01, 0.05, 0.1, 0.5 and 1µmol/plate of stercobilin were able 
to reduce the number of revertants significantly (p<0.05) from positive control 
values. Surprisingly, the tested concentration 2µmol/plate provoked a number of 
revertants that was slightly above the positive control level (about 105%). 
Therefore, statistical analysis did not show significant results for this 
concentration (p=1.000).  
 
 
 
 
 
 
 
   
 
Figure 19: The modulatory effects of bile pigments, stercobilin ▲- - - ▲ (S) 
        and urobilin ♦      ♦ (U) towards AFB1 induced genotoxicity in         
        TA102 Salmonella typhimurium (S≤1µmol/plate, U at all     
         concentrations tested, p<0.05) 
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7.2.3 Mutagenicity induced by t-BuOOH without S9 
t-BuOOH (0.75*10-6 mol/plate) induced genotoxicity was used to investigate the 
possible antioxidant effects of stercobilin and urobilin. When metabolic 
activation was absent, the bile pigments provoked an inconclusive effect that 
cannot be observed as antioxidant. Stercobilin and urobilin were not able to 
reduce the number of revertants in a dose dependent manner. It can be seen 
from Figure 20 that urobilin was more effective than stercobilin. However, none 
of the tested concentrations afforded a significant protection against t-BuOOH 
induced pro-oxidative effects (p>0.05). Stercobilin caused a significant effect at 
the concentrations 0.05, 0.1 and 1µmol/plate. Nevertheless, this bile pigment 
did not reveal any antioxidant potential under the chosen test conditions. It is 
crucial to note that these results do not imply promutagenicity of bile pigments. 
In summary, these findings suggest that stercobilin and urobilin were not able to 
attenuate t-BuOOH induced mutation.  
 
 
 
 
 
 
 
 
Figure20: The modulatory effects of bile pigments, stercobilin ▲- - - ▲ (S) and 
       urobilin ♦         ♦ (U) towards t-BuOOH induced genotoxicity in TA102 
       Salmonella typhimurium (S at 1, 0.1 and 0.05µmol/plate, p<0.05) 
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7.2.4 Mutagenicity induced by t-BuOOH with S9 
As mentioned above, this mutagen was used to elucidate the potential 
antioxidant properties of stercobilin and urobilin. When metabolic activation was 
utilized in this test model, weak antioxidant effects of both compounds could be 
observed.   
The bile pigments inhibited the t-BuOOH induced mutagenic response not in a 
dose dependent manner. Urobilin reduced the number of revertants significantly 
different from positive control values at or above 0.01µmol/plate (p<0.05).  
Although some stercobilin concentrations were able to decrease the number of 
revertants to half the positive control level, none of the tested concentrations 
showed significant differences (p>0.05).     
 
 
 
 
 
 
 
 
Figure 21: The modulatory effects of bile pigments, stercobilin ▲- - - ▲ (S) and    
       urobilin ♦        ♦ (U) towards t-BuOOH with S9 induced genotoxicity in  
       TA102 Salmonella typhimurium (U≥0.01µmol/plate, S at all     
       concentrations tested, p<0.05) 
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Numerous studies have been carried out during the past investigating the 
beneficial effects of bile pigments. These studies focused predominantly on the 
antimutagenic and antioxidant effects of bilirubin, biliverdin and related pyrrole 
pigments including hemin and chlorophyllin. However, available data on the 
beneficial effects of stercobilin and urobilin are sparse and therefore, this project 
attempted to fill this gap in current research. The present study aimed to test 
whether stercobilin and urobilin could selectively suppress the genotoxic effects 
of specific mutagens with different conformations.  
In Salmonella typhimurium strain TA98, both bile pigments were able to inhibit 
the mutagenicity of TNFone, PhiP and AFB1. In the presence of this tester 
strain, stercobilin was the most effective antimutagen for PhiP. Urobilin was 
most active for AFB1. As mentioned earlier, tester strain TA98 is suitable for 
detecting frameshift mutations [MARON and AMES, 1983]. 
More precisely, in the presence of 0.3*10-6 mol TNFone per plate, stercobilin 
was more effective than urobilin. The bile pigment dose that inhibited 
mutagenicity to 50% of the positive control was found to be approximately 
3µmol for stercobilin and 4µmol for urobilin. Therefore, the inhibition potency 
was in the order S>U (see Figure 15).  
In a recently published study, bilirubin, biliverdin and bilirubin ditaurate were 
tested for their potency to inhibit the mutagenicity of TNFone in Salmonella 
typhimurium strain TA98. All three compounds suppressed this genotoxic effect 
in a dose dependent manner (BR≥BRT>BV) [BULMER et al., 2007].                                              
Taken together, these findings as well as our achieved results suggest that 
stercobilin, urobilin, bilirubin, biliverdin and bilirubin ditaurate influenced the 
impact of TNFone to destroy DNA structure [BULMER et al., 2008].     
Concerning the PhiP results, stercobilin and urobilin showed strong 
antimutagenic effects in the presence of metabolic activation. 0.1*10-8 mol of 
PhiP were added to each plate. Both compounds were potent antimutagens 
which reduced the number of histidine revertants dose-related and significantly 
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different from positive control (p<0.05). In Salmonella typhimurium strain TA98, 
stercobilin was the most effective antimutagen for PhiP. Since there are no 
published studies available dealing with the modulatory effects of bile pigments 
towards PhiP induced genotoxicity, comparative results are lacking.     
As previously mentioned, urobilin was the most potent antimutagen for AFB1 in 
the presence of Salmonella typhimurium tester strain TA98. A remarkable ID75 
of 0.18µmol as well as an Imax of approximately 80% could be observed. As 
shown in Figure17, AFB1 induced genotoxicity (1.2*10-8 mol/plate) was less 
strongly inhibited by stercobilin. Therefore, the order of effectiveness was U>S. 
In the present study, antimutagenicity of stercobilin and urobilin towards AFB1 
induced genotoxicity was tested for the first time, therefore comparative data 
are missing.  
In 1995, Breinholt et al. studied the antimutagenic properties of chlorophyllin 
against the mutagenicity of AFB1. It was shown that this compound of 
porphyrin-like structure suppressed AFB1 induced cancer in fish [BREINHOLT 
et al., 1995].  
 TNFone PhiP AFB1 
Stercobilin - ↓↓↓ - 
Urobilin ↓ ↓↓ ↓↓↓ 
  Table 10: Modulatory effects of stercobilin and urobilin in Salmonella   
                 typhimurium strain TA98 
        -      ID50 not calculable   
        ↓      50% inhibition of positive control at 2µmol/plate  
       ↓↓      50% inhibition of positive control between 1 and 0.1µmol/plate and at 
       0.01 and 0.001 µmol/plate 
      ↓↓↓      50% inhibition of positive control at each concentration  
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In Salmonella typhimurium strain TA102, stercobilin and urobilin showed 
different modulatory effects against the induced mutagenicity of TNFone, AFB1 
and t-BuOOH. In the presence of strain TA102, stercobilin and urobilin were the 
most effective antimutagens for TNFone and AFB1, respectively.  
As mentioned above, this tester strain was used for the first time by Bulmer et 
al. in 2007 who studied the antimutagenic and antioxidant properties of bilirubin, 
biliverdin and bilirubin ditaurate [BULMER et al., 2007]. This tester strain is 
sensitive to mutagens causing oxidative damage [MARON and AMES, 1983].  
In the presence of 0.2*10-7mol TNFone per plate, urobilin was more effective 
than stercobilin. The ID50 of urobilin was approximately half of that for stercobilin 
(3.35, 1.4µmol, respectively) and therefore the order of effectiveness was U>S. 
Interestingly, this trend was not consistent in both tester strains. As previously 
described, in TA98 the reverse order could be observed.  
These positive findings agreed with the results gained by Bulmer et al. in 2007. 
In this study, bilirubin, biliverdin and bilirubin ditaurate inhibited the TNFone 
induced mutagenic response dose-related [BULMER et al., 2007]. 
Mutagenicity caused by AFB1 in the presence of Salmonella typhimurium strain 
TA102 was prevented most effectively by urobilin, whereas weaker 
antimutagenic effects were observed for stercobilin. The AFB1 concentration 
chosen was 120µg/ml, which means that 2.9*10-7mol of AFB1 were added to 
each plate. Urobilin was found to inhibit the mutagenicity of AFB1 dose-related 
and significantly different from positive control values at all concentrations 
tested (p<0.05). This trend was consistent in both tester strains and therefore 
suggests that urobilin is a very strong antimutagen for AFB1. As mentioned 
before, unfortunately there are no comparative data available.  
In order to investigate the antioxidant potential of stercobilin and urobilin, t-
BuOOH induced pro-oxidative effects were used. The modulatory effects of 
both compounds on t-BuOOH induced mutation were similar with and without 
metabolic activation. 0.75*10-6 mol of the mutagen were added to each plate.  
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When metabolic activation was missing, stercobilin and urobilin were not 
effective in inhibiting the mutagenicity of t-BuOOH in Salmonella typhimurium 
TA102 (see Fig.20). More precisely, urobilin was less active and stercobilin had 
no effect.  
In the presence of metabolic activation, both compounds were not able to 
reduce number of revertants to half of the positive control (see Fig.21). Taken 
together, stercobilin and urobilin did not reveal antioxidant effects towards t-
BuOOH induced genotoxicity.  
The results obtained differ from a recently published study where bilirubin and 
biliverdin were demonstrated to inhibit t-BuOOH induced mutation [BULMER et 
al., 2007]. Under these conditions, bilirubin was more effective than biliverdin.  
A growing body of evidence supports the view that bilirubin possesses strong 
antioxidant properties and acts as a chain-breaking compound [STOCKER et 
al., 1987a].  
Furthermore, there is increasing evidence that the antioxidant potential of 
bilirubin could be explained by bilirubin´s capacity to donate two electrons and 
form a non-radical complex. Stocker et al. demonstrated that biliverdin can only 
accept one electron [STOCKER et al., 1987]. This fact could be a possible 
explanation why bilirubin was more effective than biliverdin in inhibiting t-
BuOOH induced mutagenic response.   
As mentioned above, in the presence of t-BuOOH, stercobilin and urobilin 
showed inconclusive effects that cannot be observed as being antioxidant. 
Unfortunately there are no comparative data available on the antioxidant 
properties of stercobilin and urobilin towards mutagenicity induced by t-BuOOH. 
Therefore further research is needed to confirm or refute our findings in the here 
presented study.                                                                                                                                
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 TNFone AFB1 
t-BuOOH     
(-S9) 
t-BuOOH         
(+S9) 
Stercobilin - ↓ - ↓↓↓ 
Urobilin ↓↓↓ ↓↓ - ↓↓ 
Table 11: Modulatory effects of stercobilin and urobilin in Salmonella    
                typhimurium strain TA102 
         -      ID50 not calculable   
        ↓      50% inhibition of positive control at 0.01µmol/plate 
       ↓↓      50% inhibition of positive control at 1 and 0.05µmol/plate (AFB1) and 
       at 1 and 0.5µmol/plate (t-BuOOH +S9) 
      ↓↓↓      50% inhibition of positive control at 2, 0.1 and 0.05µmol/plate   
                  (stercobilin) and at 2, 1 and 0.5µmol/plate (urobilin) 
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7.3 Mutagenicity assays  
A recent study revealed that bilirubin, biliverdin and bilirubin ditaurate had no 
mutagenicity against Salmonella typhimurium strains TA98, TA100 and TA102 
[BULMER et al., 2007]. In order to ensure the non-mutagenic potential of 
stercobilin and urobilin in the present study, mutagenicity assays were 
conducted in concentrations of 0.01 and 2µmol/plate. Ames assays were 
carried out with and without metabolic activation using TA98 and TA102 strains. 
Altogether, four tests (TA98 TNFone, TA98 PhiP and AFB1 with S9, TA102 
TNFone and t-BuOOH and TA102 AFB1 and t-BuOOH with S9) were performed 
to confirm non-mutagenic potential of the bile pigments.  
Obviously, stercobilin and urobilin did not show any mutagenic effects in TA98 
and TA102 (see Figure 23-26). This was true for every chosen test condition. All 
tested concentrations were significantly different from doubled negative control 
values (p<0.001) and significantly different from positive control values 
(p>0.05).  
The following figures 23-26 show that none of the mutagenicity assays provided 
a dose-related increase in the number of revertant colonies. Furthermore, a 
two-fold increase of revertants could not be noticed in any test. Single revertant 
numbers as well as positive/negative control values for each test can be found 
in chapter 12 (Table 22-36). Generally it can be said that all data were situated 
in the negative control range. Interestingly, the majority of tested bile pigment 
concentrations reduced the number of histidine revertants compared to the 
negative control (DMSO).   
 
 
 
 
 
Figure 22: TA98 colonies in a           
        mutagenicity assay without      
        metabolic activation (urobilin) 
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Figure 23: Non-mutagenic potential of stercobilin (S) and urobilin (U) 
        towards TNFone induced genotoxicity in TA98 Salmonella 
        typhimurium (* *, p<0.001 significantly different to the  
        negative control) 
Figure 24: Non-mutagenic potential of stercobilin (S) and urobilin (U)         
        towards PhiP and AFB1 induced genotoxicity in TA98       
        Salmonella typhimurium (* *, p<0.001 significantly                            
        different to the negative control) 
                                                                                                                              
                                                                                                     Results and Discussion 
 
69 
 
** 
** 
** 
** 
** 
** 
** 
** 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Non-mutagenic potential of stercobilin (S) and urobilin (U)                           
        towards TNFone and t-BuOOH induced genotoxicity in TA102          
        Salmonella typhimurium (* *, p<0.001 significantly different to                                    
        the negative control ) 
Figure 26: Non-mutagenic potential of stercobilin (S) and urobilin (U) 
        towards AFB1 and t-BuOOH induced genotoxicity in TA102 
        Salmonella typhimurium (* *, p<0.001 significantly different 
        to the negative control) 
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8  CONCLUSION 
 
The aim of the present study was to investigate the antimutagenic and 
antioxidant potential of stercobilin and urobilin in the Ames Salmonella test. This 
is the first study to report that degradation products of bilirubin possess 
modulatory effects towards the genotoxicity of different mutagens. In 
continuation of formerly published data on a variety of bile pigments including 
bilirubin and biliverdin, novel findings of the present study might be of great 
physiological relevance.  
As mentioned at the beginning, this study was part of the project: ‘The 
physiological relevance of bile pigments in vitro to in vivo evidence of 
antioxidant, antimutagenic and anti-carcinogenic potential and their 
mechanisms of action’. In the course of this project the protective effects of 
eight bile pigments (bilirubin, biliverdin, bilirubin ditaurate, protoporphyrin, 
bilirubin dimethyl ester, biliverdin dimethyl ester, stercobilin and urobilin) were 
investigated in bacterial system, cell culture experiments and a human trial.  
Experiments in the bacterial system revealed that stercobilin and urobilin alone 
did not induce mutagenicity in TA98 and TA102. All presented data were 
significantly different from doubled negative control values (p<0.001) and 
significantly different from positive control values (p>0.05). This fact supports 
antimutagenicity of bile pigments and their physiological importance. 
Antimutagenic testing in the presence of Salmonella typhimurium TA98 and 
TA102 indicated that stercobilin and urobilin possessed antimutagenic 
properties against the mutagenicity induced by TNFone, PhiP and AFB1.  
Almost all experimental data were significantly different from positive control 
values (p<0.05). Chapter 12 includes all single revertant numbers, 
positive/negative control values, mean values and standard deviations. An 
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Antimutagenic potential could be observed independent of tester strain and 
metabolic activation.  
TNFone induced mutagenic response was used to investigate the 
antimutagenic potential of stercobilin and urobilin in the absence of metabolic 
activation. The results clearly show that both compounds were able to suppress 
the TNFone induced genotoxic effect dose-related in TA98 and TA102. The 
order of effectiveness according to ID50 values was S>U for TA98 and U>S for 
TA102. However, TA98 provided weaker antimutagenic effects, especially at 
lower concentrations.  
PhiP induced mutagenicity was used to test the possible antimutagenic effects 
of stercobilin and urobilin in the presence of metabolic activation. Assays were 
conducted with Salmonella typhimurium strain TA98. Both compounds showed 
strong antimutagenic effects against the genotoxicity of this food related 
mutagen. The order of effectiveness was S>U.  
Another food related mutagen, aflatoxin (AFB1), was used to investigate the 
antimutagenic potential of stercobilin and urobilin in the presence of metabolic 
activation. Antimutagenic testing with this mutagen was carried out with 
Salmonella typhimurium strain TA98 and TA102. Mutagenicity caused by AFB1 
was prevented most effectively by urobilin, whereas weaker antimutagenic 
effects were observed for stercobilin. This trend was consistent in both tester 
strains (U>S).  
In order to determine the antioxidant potential of stercobilin and urobilin, pro-
oxidative effects of an organic hydroperoxide were used. Regarding Salmonella 
typhimurium strain TA102 in the antioxidant assays, stercobilin and urobilin 
could not show protection against oxidative stress induced by t-BuOOH. 
However, in the presence of metabolic activation, both compounds showed a 
tendency to act as antioxidant.  
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Summarizing the results of the antimutagenic assays in TA98 and TA102, 
strong antimutagenic potential (PhiP, AFB1 TA98 and TNFone) as well as 
antimutagenic tendencies (AFB1 TA102) of stercobilin and urobilin were 
observed in the presence of all mutagens. Most significant results were 
obtained against the mutagenicity induced PhiP (both compounds) and the 
mutagenicity of AFB1 (urobilin). 
Summarizing the findings of the antioxidant assays in TA102, no protective 
effect was observed towards the genotoxicity of t-BuOOH without metabolic 
activation. However, stercobilin and urobilin showed weak antioxidant effects in 
the presence of metabolic activation.  
The total findings of the present study suggest that both degradation products of 
bilirubin, stercobilin and urobilin, possess broad ranging antimutagenic effects 
against a variety of mutagens in the Ames Salmonella test. Nevertheless, 
further confirmation of our findings is required to clarify the mechanisms of 
antimutagenic action. Furthermore, more research is needed to determine the 
antioxidant potential of stercobilin and urobilin.   
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9 SUMMARY 
 
The aim of the present study was to investigate the antimutagenic and 
antioxidant potential of the bile pigments, stercobilin and urobilin, in the Ames 
Salmonella test. The experiments in the bacterial system were designed with 
two Salmonella typhimurium tester strains, TA98 and TA102. Different 
mutagens including 2, 4, 7- trinitro-9-fluorenone (TNFone), aflatoxin B1 (AFB1), 
2-amino-1-methyl-6-phenylimidazo [4, 5,-b] pyridine (PhiP) und tert-
butylhydroxyperoxide (t-BuOOH) were used to confirm the formation of mutant 
revertants. Six doses of stercobilin (0.01, 0.05, 0.1, 0.5, 1 and 2 µmol/plate) and 
eight doses of urobilin (0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1 and 2 µmol/plate) 
were screened. In order to ensure non-mutagenic potential of bile pigments, 
mutagenicity assays were performed. Tests were conducted without (TNFone, 
t-BuOOH) and with (PhiP, AFB1 and t-BuOOH) metabolic activation.   
Summarizing the results of the present study, stercobilin and urobilin could 
afford significant protection against TNFone, PhiP and AFB1 induced 
mutagenicity. Antimutagenicity was observed in the presence of these three 
mutagens independent of tester strain and metabolic activation. Antioxidant 
testing in the TA102 strain revealed that stercobilin and urobilin could not 
effectively inhibit the genotoxic effects of t-BuOOH induced oxidative mutations. 
Therefore, stercobilin and urobilin showed weak antioxidant effects in this test 
system.  
To conclude, these findings suggest apparent beneficial properties of stercobilin 
and urobilin. During the course of this project, further research will be done in 
this field exploring the mechanisms of antimutagenic and antioxidant action.  
Studies in literature so far have primarily focused on bilirubin and biliverdin, so 
there are no comparative data for stercobilin and urobilin in the Ames 
Salmonella test available. Therefore, results of the present study might be of 
great interest and importance for further research in this field. 
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10  ZUSAMMENFASSUNG 
 
Das Ziel der vorliegenden Studie war die Abschätzung des antimutagenen bzw. 
antioxidativen Potentials von den beiden Gallenpigmenten Stercobilin und 
Urobilin im in vitro Ames Test. Für die Untersuchung wurden die 
Bakterienstämme Salmonella typhimurium TA98 und TA102 verwendet. Als 
mutagene Substanzen wurden  2, 4, 7- Trinitro-9-Fluorenon (TNFone), Aflatoxin 
B1 (AFB1), 2-Amino-1-methyl-6-phenylimidazo [4, 5,-b] Pyridin (PhiP) und tert-
Butylhydroxyperoxide (t-BuOOH) herangezogen. Die Testkonzentrationen der 
Gallenfarbstoffe reichten von 0.001 bis 2 µmol/Platte (Urobilin) bzw. von 0.01 
bis 2 µmol/Platte (Stercobilin). Um sicherzustellen, dass die beiden 
Gallenpigmente kein mutagenes Potential aufweisen, wurde dies in 
Mutagenitätstests überprüft. Die Tests wurden sowohl ohne (TNFone, t-
BuOOH) als auch mit (PhiP, AFB1, t-BuOOH) metabolischer Aktivierung 
durchgeführt.   
Die Ergebnisse der vorliegenden Studie haben gezeigt, dass die beiden 
Gallenpigmente antimutagenes Potential gegenüber TNFone, PhiP und AFB1 
aufweisen. Die entsprechende induzierte Mutagenität konnte, unabhängig von 
Bakterienstamm und metabolischer Aktivierung, signifikant inhibiert werden. Die 
durch t-BuOOH induzierten pro-oxidativen Effekte wurden von Stercobilin und 
Urobilin nicht durchgehend signifikant gehemmt. Dies lässt bei diesem Test auf 
eine tendenzielle antioxidative Schutzwirkung der Gallenpigmente schließen.  
Zusammenfassend lässt sich sagen, dass Stercobilin und Urobilin 
antimutagene Eigenschaften aufweisen, die im Zuge des Gesamtprojektes noch 
näher erforscht und beleuchtet werden. 
Da es sich hierbei um Pigmente handelt, deren antimutagenes bzw. 
antioxidatives Potential im Ames Test noch nicht erforscht worden ist, sind 
diese Untersuchungsergebnisse möglicherweise von erheblicher 
physiologischer Relevanz und großem Interesse für weitere Forschung. 
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12    APPENDIX 
 
12.1 Antimutagenic assays with TA98 
12.1.1  Single revertant numbers for TA98 
 
Mutagen            Bile pigment dose [µmol/plate] 
                           2            1            0.5         0.1        0.05         0.01         0.005         0.001 
TNFone 
Stercobilin 
303 347 379 500 460 554 - - 
312 343 384 427 472 567 - - 
306 345 381 480 470 461 - - 
mean 307 345 381 469 467 527 - - 
sd 4.6 2.0 2.5 37.7 6.4 57.8 - - 
% of Pos 67.8 76.2 84.2 103.6 103.2 116.5 - - 
sd % of Pos 1.0 0.4 0.6 8.3 1.4 12.8 - - 
Urobilin 
181 264 284 402 532 572 621 634 
192 269 294 445 494 613 594 582 
163 268 298 425 499 534 611 630 
mean 179 267 292 424 508 573 609 615 
sd 14.6 2.6 7.2 21.5 20.6 39.5 13.7 28.9 
% of Pos 49.4 73.8 80.7 117.1 140.4 158.3 168.1 170.0 
sd % of Pos 4.0 0.7 2.0 5.9 5.7 10.9 3.8 8.0 
PhiP +S9 
Stercobilin 
143 196 191 199 226 257 - - 
151 202 214 221 219 242 - - 
164 182 196 215 230 241 - - 
mean 153 193 200 212 225 247 - - 
sd 10.6 10.3 12.1 11.4 5.6 9.0 - - 
% of Pos 31.1 39.4 40.9 43.2 45.9 50.3 - - 
sd % of Pos 2.2 2.1 2.5 2.3 1.1 1.8 - - 
Urobilin 
123 226 272 268 261 266 292 236 
147 238 255 237 302 246 290 269 
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142 250 230 250 259 239 254 232 
mean 137 238 252 252 274 250 279 246 
sd 12.7 12.0 21.1 15.6 24.3 14.0 21.4 20.3 
% of Pos 28.1 48.7 51.7 51.5 56.1 51.3 57.1 50.3 
sd % of Pos 2.6 2.5 4.3 3.2 5.0 2.9 4.4 4.2 
PhiP S9 Repetition 
Stercobilin 
123 143 174 162 189 195 - - 
131 159 180 172 192 181 - - 
111 162 185 178 175 - - - 
mean 122 155 180 171 185 188 - - 
sd 10.1 10.2 5.5 8.1 9.1 9.9 - - 
% of Pos 30.9 39.3 45.6 43.4 47.1 47.8 - - 
sd % of Pos 2.6 2.6 1.4 2.1 2.3 2.5 - - 
AFB1 +S9 
Stercobilin 
302 191 180 175 201 207 - - 
256 182 193 171 212 134 - - 
262 165 181 169 195 134 - - 
mean 273 179 185 172 203 158 - - 
sd 25.0 13.2 7.2 3.1 8.6 42.1 - - 
% of Pos 111.3 73.0 75.2 69.9 82.5 64.5 - - 
sd % of Pos 10.2 5.4 2.9 1.2 3.5 17.2 - - 
Urobilin 
71 76 71 82 78 92 104 116 
68 70 69 78 77 99 91 106 
70 71 79 79 61 102 112 118 
mean 70 72 73 80 72 98 102 113 
sd 1.5 3.2 5.3 2.1 9.5 5.1 10.6 6.4 
% of Pos 22.0 22.9 23.1 25.2 22.8 30.9 32.3 35.8 
sd % of Pos 0.5 1.0 1.7 0.7 3.0 1.6 3.4 2.0 
AFB1 +S9 Repetition 
Stercobilin 
196 209 175 243 204 176 - - 
206 214 172 196 183 168 - - 
167 166 153 190 175 154 - - 
mean 190 196 167 210 187 166 - - 
sd 20.3 26.4 11.9 29.0 15.0 11.1 - - 
% of Pos 62.6 64.8 55.0 69.2 61.8 54.8 - - 
sd % of Pos 6.7 8.7 3.9 9.6 4.9 3.7 - - 
Table 12: Single revertant numbers of stercobilin and urobilin towards TNFone and 
      PhiP induced genotoxicity in TA98 
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12.1.2  Positive control values TA98 for Stercobilin 
 
 TNFone PhiP +S9 PhiP +S9 Repetition AFB1 +S9 
AFB1 +S9 
Repetition 
Positive I 467 463 425 291 321 
Positive II 495 481 433 284 260 
Positive III 396 527 323 162 328 
mean  453 490 394 246 303 
sd 51.0 33.0 61.3 72.5 37.4 
% of Pos 100 100 100 100 100 
sd % of Pos 11.3 6.7 15.6 29.5 12.3 
Table 13: Positive control values for TNFone, PhiP and AFB1 in TA98 (Stercobilin) 
 
12.1.3  Negative control values TA98 for Stercobilin 
 
 TNFone PhiP +S9 PhiP +S9 Repetition AFB1 +S9 
AFB1 +S9 
Repetition 
Negative I 26 57 73 44 49 
Negative II 33 59 80 47 51 
Negative III 51 64 70 41 52 
Negative IV 50 62 70 47 55 
Negative V 43 52 70 63 48 
Negative VI 39 51 67 61 42 
mean  40 58 72 51 50 
sd 9.8 5.2 4.5 9.2 4.4 
% of Pos 8.9 11.7 18.2 20.6 16.3 
sd % of Pos 2.2 1.1 1.1 3.7 1.5 
Table 14: Negative control values for TNFone, PhiP and AFB1 in TA98 (Stercobilin) 
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12.1.4  Positive control values TA98 for Urobilin  
 
 
 
TNFone PhiP +S9 AFB1 +S9 
Positive I 353 526 312 
Positive II 341 472 331 
Positive III 392 467 306 
mean  362 488 316 
sd 26.7 32.7 13.1 
% of Pos 100 100 100 
sd % of Pos 7.4 6.7 4.1 
Table15: Positive control values for TNFone, PhiP and AFB1 in TA98 (Urobilin) 
 
12.1.5  Negative control values TA98 for Urobilin 
 
 TNFone PhiP +S9 AFB1 +S9 
Negative I 30 55 55 
Negative II 35 55 55 
Negative III 38 42 42 
Negative IV 25 66 66 
Negative V 37 70 70 
Negative VI 27 42 42 
mean  32 55 55 
sd 5.4 11.7 11.7 
% of Pos 8.8 11.3 11.3 
sd % of Pos 1.5 2.4 2.4 
Table 16: Negative control values for TNFone, PhiP and AFB1 in TA98 (Urobilin) 
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12.2 Antimutagenic/antioxidant assays with TA102 
 
12.2.1  Single revertant numbers for TA102 
 
Mutagen     Bile pigment dose [µmol/plate] 
 
2 1 0,5 0,1 0,05 0,01 0,005 0,001 
TNFone 
Stercobilin 
666 676 743 760 727 815 - - 
686 693 658 774 688 991 - - 
707 793 580 695 660 1022 - - 
mean 686 721 660 743 692 943 - - 
sd 20.5 63.2 81.5 42.2 33.7 111.6 - - 
% of Pos 56.4 59.2 54.2 61.0 56.8 77.4 - - 
sd % of Pos 1.7 5.2 6.7 3.5 2.8 9.2 - - 
Urobilin 
625 509 685 769 783 1045 - - 
642 591 589 721 792 882 - - 
- 566 402 741 810 724 - - 
mean 634 555 559 744 795 884 - - 
sd 12.0 42.0 143.9 24.1 13.7 160.5 - - 
% of Pos 52.0 45.6 45.9 61.1 65.3 72.6 - - 
sd % of Pos 1.0 3.5 11.8 2.0 1.1 13.2 - - 
t-BuOOH  
Stercobilin 
1303 1412 1115 1416 1429 1462 - - 
1293 1489 1137 1382 1475 1318 - - 
- 1394 1178 1354 1501 1302 - - 
mean 1298 1432 1143 1384 1468 1361 - - 
sd 7.1 50.5 32.0 31.0 36.5 88.1 - - 
% of Pos 111.1 122.6 97.9 118.5 125.7 116.5 - - 
sd % of Pos 0.6 4.3 2.7 2.7 3.1 7.5 - - 
Urobilin 
1268 1231 1130 1567 1430 1621 1043 1436 
1152 1199 1066 1039 1423 1506 1161 1489 
1012 1249 - 1580 1449 1159 883 1431 
mean 1144 1226 1098 1395 1434 1429 1029 1452 
sd 128.2 25.3 45.3 308.7 13.5 240.5 139.5 32.1 
% of Pos 77.2 82.8 74.1 94.2 96.8 96.4 69.4 98.0 
sd % of Pos 8.7 1.7 3.1 20.8 0.9 16.2 9.4 2.2 
t-BuOOH +S9 
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Stercobilin 
1221 1503 1643 1176 1231 1524 - - 
1210 1393 1391 1230 1105 1578 - - 
1123 1445 - 1118 1226 1531 - - 
mean 1185 1447 1517 1175 1187 1544 - - 
sd 53.7 55.0 178.2 56.0 71.3 29.4 - - 
% of Pos 51.2 62.6 65.6 50.8 51.4 66.8 - - 
sd % of Pos 2.3 2.4 7.7 2.4 3.1 1.3 - - 
Urobilin 
384 482 495 553 583 521 648 697 
407 440 444 501 574 543 791 696 
621 370 285 502 324 481 629 593 
mean 471 431 408 519 494 515 689 662 
sd 130.7 56.6 109.5 29.7 147.0 31.4 88.6 59.8 
% of Pos 57.1 52.2 49.5 62.9 59.9 62.5 83.6 80.3 
sd % of Pos 15.9 6.9 13.3 3.6 17.8 3.8 10.7 7.2 
AFB1 +S9 
Stercobilin 
993 581 578 745 602 455 - - 
1180 580 601 625 963 473 - - 
1009 605 612 601 551 539 - - 
mean 1061 589 597 657 705 489 - - 
sd 103.7 14.2 17.3 77.1 224.6 44.2 - - 
% of Pos  105.2 58.4 59.2 65.2 70.0 48.5 - - 
sd % of Pos 10.3 1.4 1.7 7.7 22.3 4.4 - - 
Urobilin 
312 442 452 491 394 481 367 473 
341 474 410 484 382 495 468 427 
363 392 399 462 422 461 455 406 
mean 339 436 420 479 399 479 430 435 
sd 25.6 41.3 28.0 15.1 20.5 17.1 54.9 34.3 
% of Pos 44.3 57.1 55.0 62.7 52.3 62.7 56.3 57.0 
sd % of Pos 3.3 5.4 3.7 2.0 2.7 2.2 7.2 4.5 
Table 17: Single revertant numbers of stercobilin and urobilin towards TNFone, t-   
                BuOOH and AFB1 induced genotoxicity in TA102 
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12.2.2  Positive control values TA102 for Stercobilin 
 
 TNFone t-BuOOH t-BuOOH +S9 AFB1 +S9 
Positive I 1306 1086 1992 1006 
Positive II 1402 1250 2500 1003 
Positive III 1375 - 2444 1015 
mean  1218 1168 2312 1008 
sd 160.6 116.0 278.5 6.2 
% of Pos 100 100 100 100 
sd % of Pos 13.2 9.9 12.0 0.6 
Table 18: Positive control values for TNFone, t-BuOOH and AFB1 in TA102       
    (Stercobilin) 
 
12.2.3  Negative control values TA102 for Stercobilin 
 
 TNFone t-BuOOH t-BuOOH +S9 AFB1 +S9 
Negative I 371 341 480 421 
Negative II 318 311 465 495 
Negative III 235 323 428 415 
Negative IV 369 329 382 433 
Negative V 320 385 405 461 
Negative VI 339 310 - 445 
mean  325 333 432 445 
sd 49.8 27.9 40.7 29.6 
% of Pos 26.7 28.5 18.7 44.1 
sd % of Pos 4.1 2.4 1.8 2.9 
Table 19: Negative control values for TNFone, t-BuOOH, AFB1 in TA102     
               (Stercobilin) 
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12.2.4  Positive control values TA102 for Urobilin 
 
 TNFone t-BuOOH t-BuOOH +S9 AFB1 +S9 
Positive I 1306 1601 905 721 
Positive II 1402 1553 810 759 
Positive III 1375 1291 758 811 
mean  1218 1482 824 764 
sd 160.6 166.9 74.5 45.2 
% of Pos 100 100 100 100 
sd % of Pos 13.2 11.3 9.0 5.9 
Table 20: Positive control values for TNFone, t-BuOOH and AFB1 in TA102           
               (Urobilin) 
 
12.2.5  Negative control values TA102 for Urobilin 
 
 TNFone t-BuOOH t-BuOOH +S9 AFB1 +S9 
Negative I 371 392 237 303 
Negative II 318 411 255 291 
Negative III 235 333 292 290 
Negative IV 369 371 223 259 
Negative V 320 337 229 272 
Negative VI 339 391 185 314 
mean  325 373 237 288 
sd 49.8 31.7 35.5 20.1 
% of Pos 26.7 25.1 28.7 37.7 
sd % of Pos 4.1 2.1 4.3 2.6 
Table 21: Negative control values for TNFone, t-BuOOH and AFB1 in TA102         
                (Urobilin) 
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12.3 Mutagenicity assays with TA98 and TA102 
 
12.3.1  Single revertant numbers for TA98 without S9 
 
Mutagen                  Bile pigment dose [µmol/plate] 
 
2 0,01 
TNFone 
Stercobilin 
47 36 
42 36 
39 36 
mean 43 38 
sd 4.0 2.9 
% of Neg 76.4 67.5 
sd % of Neg 7.2 5.2 
Urobilin 
54 53 
54 53 
47 71 
mean 52 59 
sd 4.0 10.4 
% of Neg 84.2 96.2 
sd % of Neg 6.6 16.9 
Table 22: Single revertant numbers of stercobilin and urobilin towards TNFone   
                induced genotoxicity in TA98 
 
12.3.2  Positive control values TA98 without S9 for Stercobilin 
 
 TNFone 
Positive I 417 
Positive II 425 
Positive III 434 
mean 425 
sd 8.5 
Table 23: Positive control values for TNFone in TA98 (Stercobilin) 
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12.3.3  Negative control values TA98 without S9 for Stercobilin 
 
 TNFone 
Negative I 58 
Negative II 59 
Negative III 57 
Negative IV 60 
Negative V 51 
Negative VI 50 
mean 56 
sd 4.3 
% of Neg 100 
sd % of Neg 7.6 
Table 24: Negative control values for TNFone in TA98 (Stercobilin) 
 
 
12.3.4  Positive control values TA98 without S9 for Urobilin 
 
 TNFone 
Positive I 462 
Positive II 478 
Positive III 442 
mean 461 
sd 18.0 
Table25: Positive control values for TNFone in TA98 (Urobilin) 
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12.3.5  Negative control values TA98 without S9 for Urobilin 
 
 TNFone 
Negative I 63 
Negative II 62 
Negative III 56 
Negative IV 61 
Negative V 60 
Negative VI 66 
mean 61 
sd 3.3 
% of Neg 100 
sd % of Neg 5.4 
Table26: Negative control values for TNFone in TA98 (Urobilin) 
 
12.3.6  Single revertant numbers for TA102 without S9 
 
Mutagen                  Bile pigment dose [µmol/plate] 
 
2 0,01 
TNFone  
Stercobilin 
337 225 
349 243 
312 250 
mean 333 239 
sd 18.9 12.9 
% of Neg 83.0 59.7 
sd % of Neg 4.7 3.2 
Urobilin 
341 366 
353 335 
400 411 
mean 365 371 
sd 31.2 38.2 
% of Neg 92.3 93.8 
sd % of Neg 7.9 9.7 
t-BuOOH 
Stercobilin 337 225 
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349 243 
312 250 
mean 333 239 
sd 18.9 12.9 
% of Neg 83.0 59.7 
sd % of Neg 4.7 3.2 
Urobilin 
341 366 
353 335 
400 411 
mean 365 371 
sd 31.2 38.2 
% of Neg 92.3 93.8 
sd % of Neg 7.9 9.7 
Table 27: Single revertant numbers of stercobilin and urobilin towards TNFone and    
      t-BuOOH induced genotoxicity in TA102 
 
 
12.3.7  Positive control values TA102 without S9 for Stercobilin 
 
 TNFone t-BuOOH 
Positive I 1106 1653 
Positive II 1121 1641 
Positive III 1109 - 
mean 1112 1647 
sd 7.9 8.5 
Table 28: Positive control values for TNFone and t-BuOOH in TA102 (Stercobilin) 
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12.3.8  Negative control values TA102 without S9 for Stercobilin 
 
 TNFone t-BuOOH 
Negative I 397 397 
Negative II 427 427 
Negative III 395 395 
Negative IV 402 402 
Negative V 417 417 
Negative VI 367 367 
mean 401 401 
sd 20.7 20.7 
% of Neg 100 100 
sd % of Neg 5.2 5.2 
Table29: Negative control values for TNFone and t-BuOOH in TA102 (Stercobilin) 
 
 
12.3.9  Positive control values TA102 without S9 for Urobilin 
 
 TNFone t-BuOOH 
Positive I 1092 1309 
Positive II 1045 1151 
Positive III 1107 1158 
mean 1081 1206 
sd 32.3 89.3 
Table 30: Positive control values for TNFone and t-BuOOH in TA102 (Urobilin) 
 
 
 
 
 
 
                                                                                                                              
                                                                                                                                Appendix 
 
95 
 
12.3.10  Single revertant numbers for TA98 with S9 
 
Mutagen                   Bile pigment dose [µmol/plate] 
 
2 0,01 
Phip 
Stercobilin 
49 47 
51 43 
49 51 
mean 50 47 
sd 1.2 4.0 
% of Neg 98.3 93.1 
sd % of Neg 2.3 7.9 
Urobilin 
51 41 
42 45 
50 40 
mean 48 42 
sd 4.9 2.6 
% of Neg 94.4 83.2 
sd % of Neg 9.8 5.2 
AFB1 
Stercobilin 
49 47 
51 43 
49 51 
mean 50 47 
sd 1.2 4.0 
% of Neg 98.3 93.1 
sd % of Neg 2.3 7.9 
Urobilin 
51 41 
42 45 
50 40 
mean 48 42 
sd 4.9 2.6 
% of Neg 94.4 83.2 
sd % of Neg 9.8 5.2 
Table31: Single revertant numbers of stercobilin and urobilin towards PhiP and  
    AFB1 induced genotoxicity in TA98 
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12.3.11 Positive control values TA98 with S9 for Stercobilin and Urobilin 
 
 PhiP AFB1 
Positive I 349 123 
Positive II 385 151 
Positive III 422 162 
mean 385 145 
sd 36.5 20.1 
Table32: Positive control values for PhiP and AFB1 in TA98                                              
              (Stercobilin and Urobilin) 
 
12.3.12  Negative control values TA98 with S9 for Stercobilin and Urobilin 
 
 PhiP AFB1 
Negative I 56 56 
Negative II 50 50 
Negative III 48 48 
Negative IV 50 50 
Negative V 51 51 
Negative VI 48 48 
mean 51 51 
sd 2.9 2.9 
% of Neg 100 100 
sd % of Neg 5.8 5.8 
Table33: Negative control values for PhiP and AFB1 in TA98                                       
               (Stercobilin and Urobilin) 
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12.3.13  Single revertant numbers for TA102 with S9 
 
Mutagen                  Bile pigment dose [µmol/plate] 
 
2 0,01 
t-BuOOH 
Stercobilin 
361 313 
380 325 
391 307 
mean 377 315 
sd 15.2 9.2 
% of Neg 102.7 85.7 
sd % of Neg  4.1 2.5 
Urobilin 
292 307 
314 332 
306 343 
mean 304 327 
sd 11.1 18.4 
% of Neg 82.7 89.1 
sd % of Neg 3.0 5.0 
AFB1 
Stercobilin 
361 313 
380 325 
391 307 
mean 377 315 
sd 15.2 9.2 
% of Neg 102.7 85.7 
sd % of Neg 4.1 2.5 
Urobilin 
292 307 
314 332 
306 343 
mean 304 327 
sd 11.1 18.4 
% of Neg 82.7 89.1 
sd % of Neg 3.0 5.0 
Table34: Single revertant numbers of stercobilin and urobilin towards                                              
     t-BuOOH and AFB1 induced genotoxicity in TA102 
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12.3.14   Positive control values TA102 with S9 for Stercobilin and Urobilin 
 
 t-BuOOH AFB1 
Positive I 1914 725 
Positive II 2003 701 
Positive III 1902 694 
mean 1940 707 
sd 55.2 16.3 
Table 35: Positive control values for t-BuOOH and AFB1 in TA102                                               
     (Stercobilin and Urobilin) 
 
12.3.15 Negative control values TA102 with S9 for Stercobilin and Urobilin 
 
 t-BuOOH AFB1 
Negative I 388 388 
Negative II 404 404 
Negative III 327 327 
Negative IV 387 387 
Negative V 355 355 
Negative VI 344 344 
mean 368 368 
sd 29.9 29.9 
% of Neg 100 100 
sd % of Neg 8.1 8.1 
Table 36: Negative control values for t-BuOOH and AFB1 in TA102                            
     (Stercobilin and Urobilin) 
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